https://crcwarriors.org/ 2026-07-07 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-07-07 daily 0.9 https://crcwarriors.org/medicamentos 2026-07-07 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-07-07 daily 0.8 https://crcwarriors.org/noticias 2026-07-07 daily 0.8 https://crcwarriors.org/combinaciones 2026-07-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-07-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-07-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-07-01 monthly 0.7 https://crcwarriors.org/contacto 2026-07-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-07-01 monthly 0.6 https://crcwarriors.org/colabora 2026-07-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07683403/savolitinib-mas-cetuximab-y-quimioterapia-con-folfox-para-el-cancer-colorrectal-metastasico-con-mutacion-ras-braf-silvestre 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683403/savolitinib-plus-cetuximab-and-folfox-chemotherapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683949/ensayo-clinico-que-evalua-la-eficacia-de-capecitabina-mas-lenvatinib-en-pacientes-con-cancer-colorrectal-avanzado-refractario-a-irinotecan-oxaliplatino-y-fluoropirimidina 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683949/clinical-trial-evaluating-the-efficacy-of-capecitabine-plus-lenvatinib-in-patients-with-advanced-colorectal-cancer-refractory-to-irinotecan-oxaliplatin-and-fluoropyrimidine 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07685236/un-estudio-de-exploracion-de-biomarcadores-para-predecir-la-localizacion-de-la-recurrencia-y-la-metastasis-en-el-cancer-colorrectal-estudio-probe 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07685236/a-biomarker-exploration-study-for-predicting-localization-of-recurrence-and-metastasis-in-colorectal-cancer-probe-study 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-mas-radioterapia-para-la-preservacion-de-organos-en-el-cancer-de-recto 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-plus-radiotherapy-for-organ-preservation-in-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/prediccion-de-la-eficacia-de-la-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-mediante-una-plataforma-de-inteligencia-artificial-basada-en-la-resonancia-magnetica 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/predicting-the-efficacy-of-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-using-an-ai-platform-based-on-multi-parametric-mri 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06477991/eficacia-de-la-estrategia-de-observacion-y-espera-o-de-la-cirugia-tras-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-guiada-por-el-seguimiento-dinamico-de 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06477991/the-efficacy-of-watch-and-wait-strategy-or-surgery-after-neoadjuvant-immunotherapy-for-locally-advanced-colorectal-cancer-with-dmmr-msi-h-guided-by-mrd-dynamic-monitoring-a-single-center-open-label 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/un-estudio-de-fase-ii-realizado-en-un-unico-centro-sobre-la-eficacia-y-la-seguridad-de-la-combinacion-de-radioterapia-estereotactica-scrt-con-quimioterapia-capox-serplulimab-y-bevacizumab-en 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/a-single-center-phase-ii-study-on-efficacy-safety-of-scrt-capox-serplulimab-bevacizumab-for-mss-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05212012/d-l-metadona-y-mfolfox6-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-methadone-and-mfolfox6-in-treatment-of-advanced-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/quimioterapia-de-consolidacion-frente-a-quimioterapia-de-induccion-en-la-terapia-neoadyuvante-total-del-cancer-de-recto-con-alto-riesgo-de-recurrencia 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05054959/consolidation-versus-induction-chemotherapy-in-total-neoadjuvant-therapy-of-rectal-cancer-with-high-risk-for-recurrence 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/tratamiento-del-cancer-de-recto-con-quimiorradioterapia-concurrente-a-largo-plazo-combinada-con-camrelizumab 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/treatment-of-rectal-cancer-with-long-term-concurrent-chemoradiotherapy-combined-with-camrelizumab 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669298/vigilancia-activa-frente-a-quimiorradioterapia-adyuvante-en-cancer-de-recto-t1-de-riesgo-intermedio-tras-reseccion-local 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669298/active-surveillance-vs-adjuvant-chemoradiotherapy-for-locally-resected-intermediate-risk-t1-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07674732/radioterapia-de-curso-corto-con-quimio-pd-1-bevacizumab-y-radioterapia-de-curso-corto-con-quimioterapia-como-terapia-neoadyuvante-en-cancer-colorrectal-localmente-avanzado-con-pmmr-mss-con-el 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07674732/nodal-region-sparing-short-course-rt-with-chemo-pd-1-bevacizumab-vs-short-course-rt-with-chemotherapy-as-tnt-in-pmmr-mss-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07673393/mejorando-la-prediccion-del-pronostico-en-el-cancer-de-colon 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07673393/improving-prognostication-in-colon-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-solo-o-en-combinacion-con-hai-folfox-para-el-cancer-colorrectal-refractario 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-with-or-without-hai-folfox-for-refractory-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06099951/tratamiento-neoadyuvante-total-para-cancer-colorrectal-localmente-avanzado-con-pmmr-anticuerpo-anti-pd-1-con-folfoxiri-y-radioterapia-preoperatoria 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06099951/total-neoadjuvant-treatment-for-pmmr-locally-advanced-low-rectal-cancer-anti-pd-1-antibody-with-folfoxiri-and-preoperative-radiation-therapy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-y-durvalumab-en-el-tratamiento-de-pacientes-con-cancer-de-pancreas-avanzado-y-refractario-cancer-de-pulmon-no-microcitico-y-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-and-durvalumab-in-treating-patients-with-advanced-and-refractory-pancreatic-non-small-cell-lung-cancer-and-mismatch-repair-deficient-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/radioterapia-de-corta-duracion-combinada-con-furoquintinib-y-anticuerpo-monoclonal-anti-pd-1 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/short-course-radiotherapy-combined-with-furoquintinib-and-pd-1-monoclonal-antibody 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04041310/nous-209-vacuna-genetica-para-el-tratamiento-de-tumores-solidos-con-inestabilidad-de-microsatelites 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04041310/nous-209-genetic-vaccine-for-the-treatment-of-microsatellite-unstable-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/intervencion-con-alimentos-altamente-fermentados-en-pacientes-con-cancer-colorrectal-localmente-avanzado-el-estudio-feed 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/high-fermented-food-intervention-among-locally-advanced-rectal-cancer-patients-the-feed-trial 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/cambios-en-el-microbioma-intestinal-durante-la-terapia-con-abemaciclib-en-el-cancer-de-mama 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/gut-microbiome-changes-during-abemaciclib-therapy-in-breast-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/tislelizumab-neoadyuvante-en-combinacion-con-quimioterapia-para-el-tratamiento-del-cancer-colorrectal-mss 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/neoadjuvant-tislelizumab-with-chemotherapy-for-the-treatment-of-mss-colon-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06293625/personalizacion-y-optimizacion-de-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-pero-resecable-en-pacientes-de-edad-avanzada-de-70-anos-o-mas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalising-and-refining-neo-adjuvant-chemotherapy-in-locally-advanced-but-resecable-colon-cancer-in-the-elderly-of-70-years-old-or-more 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/quimioterapia-neoadyuvante-combinada-con-terapia-secuencial-con-inhibidores-de-puntos-de-control-inmunitario-ici-en-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/neoadjuvant-chemotherapy-plus-sequential-immune-checkpoint-inhibitor-ici-therapy-in-locally-advanced-colon-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07248020/un-estudio-de-fase-ii-de-un-solo-brazo-sobre-la-administracion-de-curcumina-de-alta-biodisponibilidad-como-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto-medio-a-bajo-analisis-clinico-y 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/a-phase-ii-single-arm-study-of-high-bioavailability-curcumin-as-neoadjuvant-chemoradiotherapy-in-mid-to-low-rectal-cancer-integrated-clinical-and-translational-analysis-of-tumor-tissue 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494669/proteomica-y-parametros-fisiologicos-que-predicen-complicaciones-tras-la-cirugia-de-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494669/proteomics-and-physiological-parameters-predicting-complications-after-colorectal-cancer-surgery 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/estudio-de-fase-ii-de-encorafenib-mas-cetuximab-con-retratamiento-guiado-por-ctdna-en-pacientes-con-mcrc-con-mutacion-braf-v600e 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/phase-ii-study-of-ctdna-guided-encorafenib-plus-cetuximab-retreatment-in-patients-braf-v600e-mutated-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503847/toma-de-decisiones-compartida-para-la-deteccion-del-cancer-colorrectal-en-familiares-de-primer-grado-de-alto-riesgo-de-entre-40-y-49-anos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503847/shared-decision-making-for-colorectal-cancer-screening-in-high-risk-first-degree-relatives-aged-40-49 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06930118/el-objetivo-de-este-estudio-es-evaluar-la-eficacia-y-la-seguridad-de-chidamide-regorafenib-en-combinacion-con-iparomlimab-y-tuvonralimab-para-el-tratamiento-del-cancer-colorrectal-avanzado-en-tercera 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06930118/the-aim-of-this-study-is-to-assess-the-efficacy-and-safety-of-chidamide-regorafenib-in-combination-with-iparomlimab-and-tuvonralimab-for-the-treatment-of-advanced-colorectal-cancer-in-third-line 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06833021/deteccion-de-la-proteina-x-del-virus-de-la-hepatitis-b-hbx-en-el-cancer-asociado-a-la-colitis-cac 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06833021/screening-for-hepatitis-virus-b-protein-x-hbx-in-colitis-associated-cancer-cac 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/quimioterapia-neoadyuvante-con-capox-mas-ivonescimab-frente-a-capox-en-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/neoadjuvant-capox-plus-ivonescimab-versus-capox-for-locally-advanced-colon-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-en-el-carcinoma-gastrico-y-el-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-in-locally-advanced-msi-h-dmmr-gastric-carcinoma-and-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/un-estudio-clinico-multicentrico-de-un-solo-brazo-que-evalua-la-combinacion-de-fruquintinib-con-serplulimab-y-quimioterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/a-single-arm-multicenter-clinical-study-of-fruquintinib-combined-with-serplulimab-and-chemotherapy-as-first-line-treatment-for-patients-with-ras-braf-mutated-advanced-colorectal-cance 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04034173/tratamiento-optimo-con-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-ras-de-baja-frecuencia 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04034173/optimal-anti-egfr-treatment-of-mcrc-patients-with-low-frequency-ras-mutation 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06738225/microarn-sericos-como-biomarcadores-diagnosticos-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06738225/serum-micrornas-as-diagnostic-biomarkers-of-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07192068/ensayo-clinico-que-evalua-la-actividad-de-zanidatamab-en-el-tratamiento-de-pacientes-con-tumores-solidos-que-presentan-una-alteracion-en-el-gen-her2 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07192068/clinical-trial-evaluating-the-activity-of-zanidatamab-for-the-treatment-of-patients-with-solid-tumors-with-an-alteration-of-the-her2-gene 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622771/radioterapia-neoadyuvante-combinada-con-nalirifox-y-adebrelimab-en-cancer-colorrectal-localmente-avanzado-pmmr-mss-un-ensayo-clinico-prospectivo-aleatorizado-de-fase-ii 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622771/neoadjuvant-radiotherapy-combined-with-nalirifox-and-adebrelimab-in-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-randomized-phase-ii-clinical-trial 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07632313/intervencion-sobre-habitos-de-salud-para-pacientes-con-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07632313/health-behavior-intervention-for-colorectal-cancer-patients 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-para-el-tratamiento-de-cancer-colorrectal-localmente-avanzado-irresecable-y-no-metastasico-con-dmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-for-locally-advanced-irresectable-non-metastatic-dmmr-colorectal-cancers 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05973487/un-estudio-basket-de-terapias-celulares-autologas-de-tcr-t-personalizadas-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/a-basket-study-of-customized-autologous-tcr-t-cell-therapies-in-patients-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radioterapia-combinada-con-ql1706-tas-102-y-bevacizumab-en-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06654037/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-abemaciclib-al-tratamiento-quimioterapeutico-habitual-5-fluorouracilo-para-el-cancer-colorrectal-metastasico-y-refractario 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06654037/testing-the-addition-of-an-anti-cancer-drug-abemaciclib-to-the-usual-chemotherapy-treatment-5-fluorouracil-for-metastatic-refractory-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/diferentes-dosis-de-radioterapia-estereotactica-scrt-mas-capox-bloqueo-de-pd-1-e-il-2-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/different-dose-scrt-plus-capox-pd-1-blockade-and-il-2-in-larc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06597955/implementacion-a-gran-escala-de-una-herramienta-de-apoyo-a-la-toma-de-decisiones-sobre-la-deteccion-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06597955/large-scale-implementation-of-a-decision-aid-about-colorectal-cancer-screening 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06647680/quimioterapia-neoadyuvante-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado-control-01 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/neoadjuvant-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer-control-01 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07038122/reduccion-del-margen-de-reseccion-tras-la-terapia-neoadyuvante-en-canceres-localmente-avanzados-de-la-union-rectosigmoidea-y-del-recto-superior 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosigmoid-junction-cancers 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04603287/un-estudio-de-si-b001-un-anticuerpo-bispecifico-anti-egfr-her3-en-tumores-epiteliales-localmente-avanzados-o-metastasicos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04603287/a-study-of-si-b001-an-egfr-her3-bispecific-antibody-in-locally-advanced-or-metastatic-epithelial-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07021950/ak112-mas-folfiri-frente-a-bevacizumab-mas-folfiri-como-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-mss-pmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07021950/ak112-plus-folfiri-versus-bevacizumab-plus-folfiri-as-second-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04024917/impacto-de-la-coherencia-cardiaca-en-la-ansiedad-de-pacientes-sometidos-a-cirugia-por-carcinomatosis-peritoneal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04722341/la-alimentacion-restringida-en-el-tiempo-y-el-cancer-resultados-clinicos-mecanismos-y-factores-moduladores 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04722341/time-restricted-eating-and-cancer-clinical-outcomes-mechanisms-and-moderators 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03981497/ablacion-por-microondas-para-el-tratamiento-de-tumores-renales-pequenos-y-neoplasias-hepaticas-primarias-y-secundarias 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/microwave-ablation-for-treatment-of-small-renal-tumors-and-primary-and-secondary-liver-neoplasms 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07108517/una-intervencion-manualizada-para-promover-el-crecimiento-postraumatico-en-personas-con-cancer-en-grecia-ic-growth 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07108517/a-manualized-post-traumatic-growth-intervention-for-people-with-cancer-in-greece-ic-growth 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06018714/eficacia-del-fruquintinib-modificado-en-metastasis-hepaticas-del-cancer-colorrectal-un-estudio-de-fase-ii 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06018714/efficacy-of-modified-fruquintinib-in-colorectal-cancer-liver-metastases-a-phase-ii-study 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07544784/ak104-mas-radioterapia-en-combinacion-con-la-terapia-estandar-frente-a-la-terapia-estandar-como-tratamiento-de-primera-linea-para-crlm-pmmr-mss-apsoc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07544784/ak104-plus-radiotherapy-combined-with-standard-therapy-versus-standard-therapy-as-first-line-treatment-for-pmmr-mss-crlm-apsoc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05772923/preservacion-de-organos-en-el-cancer-de-recto-braquiterapia-de-contacto-con-rayos-x-frente-a-la-prolongacion-del-intervalo-de-espera-y-la-escision-local 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/estudio-de-inmunoterapia-con-timalfasina-y-regimen-triple-en-cancer-colorrectal-avanzado-mss-pmmr 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/thymalfasin-immunotherapy-study-with-triple-regimen-in-advanced-mss-pmmr-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04149613/valor-predictivo-y-pronostico-de-los-marcadores-inflamatorios-y-los-microarn-en-el-cancer-colorrectal-en-estadio-iv 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04149613/predictive-and-prognostic-value-of-inflammatory-markers-and-microrna-in-stage-iv-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07555210/estudio-piloto-de-los-cambios-en-la-densidad-mineral-osea-durante-la-inmunoterapia-anti-pd-1 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555210/pilot-study-of-bone-mineral-density-changes-during-anti-pd-1-immunotherapy 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/diagnostico-mediante-inteligencia-artificial-de-los-diferentes-patrones-de-crecimiento-histopatologico-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/artificial-intelligence-diagnosis-of-different-histopathological-growth-patterns-of-colorectal-cancer-liver-metastasis 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07558083/ensayo-folicolor-seguimiento-de-la-respuesta-terapeutica-mediante-biopsia-liquida-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07558083/folicolor-trial-following-therapy-response-through-liquid-biopsy-in-metatstatic-colorectal-cancer-patients 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/eficacia-de-sgm-101-para-la-delimitacion-del-tumor-primario-y-de-las-recurrencias-tumorales-y-metastasis-en-pacientes-sometidos-a-cirugia-por-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/performance-of-sgm-101-for-the-delineation-of-primary-and-recurrent-tumor-and-metastases-in-patients-undergoing-surgery-for-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05118724/atezolizumab-en-pacientes-con-cancer-colorrectal-en-estadio-ii-de-alto-riesgo-y-estadio-iii-con-msi-h-dmmr-que-no-son-candidatos-para-recibir-oxaliplatino 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05118724/atezolizumab-in-patients-with-msi-h-mmr-d-stage-ii-high-risk-and-stage-iii-colorectal-cancer-ineligible-for-oxaliplatin 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-en-combinacion-con-quimiorradioterapia-neoadyuvante-como-tratamiento-de-primera-linea-para-el-cancer-de-recto-localmente-avanzado-de-alto-riesgo-y-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-combined-with-neoadjuvant-chemoradiotherapy-as-first-line-treatment-for-locally-advanced-high-risk-mss-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/estudio-de-cohorte-prospectivo-sobre-la-ablacion-termica-de-tumores-hepaticos-malignos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/prospective-cohort-study-on-thermal-ablation-of-malignant-liver-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/quimioterapia-neoadyuvante-con-inhibidores-de-pd-1-combinada-con-sib-imrt-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/neoadjuvant-chemotherapy-with-pd-1-inhibitors-combined-with-sib-imrt-in-the-treatment-of-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06809660/efectos-de-los-disruptores-endocrinos-en-la-microbiota-intestinal-y-evaluacion-de-su-impacto-en-el-desarrollo-del-cancer-colorrectal-permica 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06809660/effects-of-endocrine-disruptors-on-the-gut-microbiota-and-assessment-of-their-impact-on-colorectal-cancer-development-permica 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07123441/un-estudio-sobre-la-eficacia-y-la-seguridad-del-liposoma-de-irinotecan-ii-5-fu-lv-en-combinacion-con-bevacizumab-para-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07123441/a-study-on-the-efficacy-and-safety-of-irinotecan-liposome-ii-5-fu-lv-in-combination-with-bevacizumab-for-the-treatment-of-advanced-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167409/un-estudio-de-evorpacept-alx148-en-combinacion-con-cetuximab-y-pembrolizumab-para-el-cancer-colorrectal-metastasico-refractario-con-estabilidad-de-microsatelites 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167409/a-study-of-evorpacept-alx148-with-cetuximab-and-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04842006/control-sistemico-neoadyuvante-y-adyuvante-mediante-medicina-de-precision-en-el-cancer-de-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04842006/systemic-neoadjuvant-and-adjuvant-control-by-precision-medicine-in-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07581912/tratamiento-neoadyuvante-con-fulzerasib-mas-cetuximab-n01-en-cancer-colorrectal-localmente-avanzado-con-mutacion-kras-g12c-con-o-sin-metastasis-resecables 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403877/inmunoterapia-neoadyuvante-radioterapia-en-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/neoadjuvant-immunotherapy-radiotherapy-in-msi-h-dmmr-locally-advanced-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-en-combinacion-con-capeox-y-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-combined-with-capeox-celecoxib-as-neoadjuvant-treatment-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03926338/toripalimab-como-tratamiento-neoadyuvante-con-o-sin-celecoxib-en-cancer-colorrectal-con-dmmr-msi-h 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03926338/neoadjuvant-toripalimab-with-or-without-celecoxib-in-dmmr-msi-h-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/un-ensayo-clinico-que-compara-la-radioterapia-de-ciclo-largo-frente-a-la-radioterapia-de-ciclo-corto-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-total-tnt-frente-a-la-radioterapia-de 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/quimiorradioterapia-preoperatoria-con-capecitabina-y-temozolomida-en-cancer-colorrectal-localmente-avanzado-con-expresion-de-mgmt-silenciada-y-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/preoperative-chemoradiotherapy-with-capecitabine-and-temozolomide-in-mgmt-silenced-mss-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07210502/efectos-secundarios-de-la-braquiterapia-de-baja-dosis-y-la-radioterapia-ultrafraccionada-en-el-cancer-de-prostata-de-riesgo-bajo-a-intermedio 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/side-effects-of-low-dose-rate-brachytherapy-and-ultra-hypofractionated-radiotherapy-in-low-to-intermediate-risk-prostate-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06259552/un-estudio-de-spx-303-un-anticuerpo-bispecifico-dirigido-contra-lilrb2-y-pd-l1-en-pacientes-con-tumores-solidos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/a-study-of-spx-303-a-bispecific-antibody-targeting-lilrb2-and-pd-l1-in-patients-with-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/un-estudio-de-tumores-solidos-para-el-tratamiento-a-largo-plazo-de-pacientes-con-cancer-que-participaron-en-estudios-con-adagrasib 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/a-solid-tumor-study-for-long-term-treatment-of-cancer-patients-who-participated-in-adagrasib-studies 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05610163/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-el-irinotecan-al-tratamiento-de-quimioterapia-estandar-folfox-tras-la-radioterapia-prolongada-en-pacientes-con-cancer-de-recto-en-estadio-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05610163/testing-the-addition-of-an-anti-cancer-drug-irinotecan-to-the-standard-chemotherapy-treatment-folfox-after-long-course-radiation-therapy-for-advanced-stage-rectal-cancers-to-improve-the-rate-of 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06978400/un-estudio-de-dabrafenib-mas-cetuximab-panitumumab-con-folfox-en-la-primera-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06978400/a-study-of-dabrafenib-plus-cetuximab-panitumumab-with-folfox-in-the-first-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03975049/combinacion-triple-o-regimen-de-doble-farmaco-frente-a-quimiorradiacion-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/triplet-combination-or-doublet-regimen-versus-chemoradiation-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06267378/evaluacion-de-la-fragilidad-y-sus-efectos-en-pacientes-que-se-someten-a-una-cirugia-mayor-del-tracto-gastrointestinal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06267378/assessing-frailty-and-its-impacts-on-patients-facing-major-gi-surgery 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/estudio-para-comprender-la-relacion-entre-la-salud-intestinal-y-las-toxicidades-del-tratamiento-hormonal-del-cancer-de-mama 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/study-to-understand-relationship-between-gut-health-and-toxicities-of-hormonal-breast-cancer-treatment 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843434/un-estudio-de-botensilimab-y-balstilimab-para-el-adenocarcinoma-rectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843434/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinoma 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/un-ensayo-para-evaluar-la-seguridad-y-la-actividad-del-fruquintinib-en-poblaciones-minoritarias-con-cancer-colorrectal-avanzado-previamente-tratado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/a-trial-to-evaluate-the-safety-and-activity-of-fruquintinib-in-minority-populations-with-advanced-previously-treated-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07661017/gutcheck-optimizacion-de-una-aplicacion-movil-de-salud-personalizada-para-pacientes-que-han-sobrevivido-a-un-cancer-gastrointestinal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07661017/gutcheck-optimization-of-a-personalized-mobile-health-app-for-survivors-of-gastrointestinal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06765252/efecto-del-polimorfismo-genetico-en-la-toxicidad-inducida-por-capecitabina-en-pacientes-egipcios-con-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765252/effect-of-genetic-polymorphism-on-capecitabine-induced-toxicity-in-egyptian-cancer-patients 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911684/radioterapia-mas-iparolimab-y-tuvonalimab-ql1706-regorafenib-y-capox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911684/radiotherapy-plus-iparomlimab-and-tuvonralimab-ql1706-regorafenib-and-capox-as-neoadjuvant-therapy-for-pmmr-mss-larc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-en-combinacion-con-los-regimenes-folfox-folfiri-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-combined-with-folfox-folfiri-regimen-in-patients-with-advanced-colorectal-liver-metastases-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03921684/ensayo-clinico-de-nivolumab-en-combinacion-con-folfox-tras-quimiorradioterapia-en-pacientes-con-cancer-de-recto 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03921684/trial-of-nivolumab-with-folfox-after-chemoradiation-in-rectal-cancer-patients 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134218/quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-y-terapia-antiangiogenica-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134218/neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-and-anti-angiogenesis-in-treating-locally-advanced-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07239466/un-estudio-piloto-que-evalua-la-suplementacion-con-hidroxibutirato-en-combinacion-con-radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-con-capeox-en 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07239466/a-pilot-study-evaluating-hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06501482/quimioterapia-adyuvante-basada-en-folfiri-tras-la-reseccion-de-metastasis-hepaticas-que-responden-a-la-quimioterapia-neoadyuvante-con-folfiri 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06501482/adjuvant-folfiri-based-chemotherapy-after-resection-of-clm-responding-to-preoperative-folfiri 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/tomografia-computarizada-con-detector-de-fotones-de-conteo-y-contraste-pcd-ct-para-la-estadificacion-local-del-cancer-de-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/contrast-enhanced-photon-counting-detector-ct-pcd-ct-for-the-local-staging-of-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718543/radioterapia-neoadyuvante-de-corta-duracion-con-o-sin-quimioterapia-y-ak112-en-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718543/neoadjuvant-short-course-radiotherapy-with-or-without-chemotherapy-and-ak112-in-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/radioterapia-de-baja-dosis-con-conservacion-de-los-ganglios-linfaticos-administrada-de-forma-concurrente-con-quimioterapia-e-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmr-mss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06516445/radioterapia-de-corta-duracion-seguida-de-camrelizumab-en-combinacion-con-fluzoparib-y-quimioterapia-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06516445/scrt-followed-by-camrelizumab-combined-with-fluzoparib-and-chemotherapy-as-neoadjuvant-therapy-for-larc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903325/un-estudio-clinico-multicentrico-prospectivo-sobre-el-seguimiento-dinamico-de-los-marcadores-de-metilacion-del-ctdna-plasmatico-para-predecir-la-recurrencia-del-cancer-colorrectal-tras-la-reseccion 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903325/a-prospective-multicentre-clinical-study-of-dynamic-monitoring-of-plasma-ctdna-methylation-markers-to-predict-recurrence-of-colorectal-cancer-after-complete-resection-of-peritoneal-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-quimioterapia-con-tas-102-mas-radioterapia-neoadyuvante 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/treating-locally-advanced-rectal-cancer-with-tas-102-chemotherapy-plus-neoadjuvant-radiotherapy 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/ensayo-clinico-de-mfolfox-neoadyuvante-mas-alvenor-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-con-alta-expresion-de-ywhab 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/clinical-trial-of-neoadjuvant-mfolfox-plus-alvenor-for-larc-patients-with-high-ywhab-expression 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405776/efecto-de-la-lidocaina-sobre-el-dolor-postoperatorio-y-la-supervivencia-a-largo-plazo-en-pacientes-geriatricos-sometidos-a-cirugia-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405776/effect-of-lidocaine-on-postoperative-pain-and-long-term-survival-in-elderly-patients-undergoing-colorectal-surgery 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-quimioterapia-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-de-microsatelites-un-ensayo-clinico-prospectivo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/short-course-radiotherapy-followed-by-immunotherapy-combined-with-chemotherapy-for-microsatellite-stable-locally-advanced-rectal-cancer-a-prospective-randomized-controlled-phase-ii-clinical-trial 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03748485/quimioterapia-adyuvante-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-localmente-avanzado-tras-la-administracion-de-terapias-preoperatorias-y-con-un-diagnostico-de-pt0-3n0m0 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03748485/adjuvant-chemotherapy-in-clinical-local-advanced-crc-following-preoperational-therapies-and-pt0-3n0m0-diagnosis 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/un-estudio-sobre-la-quimioterapia-paliativa-en-segunda-linea-y-posteriores-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/a-study-of-second-and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06603376/inyeccion-liposomal-de-irinotecan-clorhidrato-ii-combinada-con-fluorouracilo-acido-folinico-vermofenib-y-cetuximab-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-avanzado-con-mutacion 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06603376/irinotecan-hydrochloride-liposome-injection-ii-combined-with-fluorouracil-folinic-acid-vermofenib-and-cetuximab-in-first-line-treatment-of-brafv600e-mutated-advanced-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/trasplante-de-la-microbiota-intestinal-para-el-tratamiento-de-la-caquexia-tumoral-avanzada 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05605353/aprovechando-el-potencial-del-microbioma-intestinal-y-sus-metabolitos-en-el-cancer-pelvico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05605353/exploiting-the-gut-microbiota-and-its-metabolites-in-pelvic-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02732860/modelado-personalizado-de-xenoinjertos-derivados-del-paciente-ppdx-para-evaluar-la-respuesta-a-farmacos-en-un-huesped-compatible 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02732860/personalized-patient-derived-xenograft-ppdx-modeling-to-test-drug-response-in-matching-host 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/tratamiento-neoadyuvante-con-shr-1701-mas-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05129774/quimiorradioterapia-seguida-de-cirugia-radical-en-pacientes-con-cancer-colorrectal-con-palnm 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03516708/se-anade-epacadostat-incb024360-a-la-quimiorradiacion-preoperatoria-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03516708/epacadostat-incb024360-added-to-preoperative-chemoradiation-in-patients-with-locally-advanced-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01061515/oxaliplatino-intraperitoneal-administrado-cada-dos-semanas-junto-con-capecitabina-y-bevacizumab-por-via-sistemica-para-pacientes-con-carcinomatosis-peritoneal-procedente-de-cancer-de-apendice-o 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01061515/biweekly-intraperitoneal-oxaliplatin-with-systemic-capecitabine-and-bevacizumab-for-patients-with-peritoneal-carcinomatosis-from-appendiceal-or-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/ensayo-collision-relapse 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/collision-relapse-trial 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/seguridad-y-eficacia-de-fruquintinib-mas-chidamide-y-sintilimab-en-el-tratamiento-de-tercera-linea-o-posterior-del-cancer-colorrectal-metastasico-mss-pmmr 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/safety-and-efficacy-of-fruquintinib-plus-chidamide-and-sintilimab-in-the-third-and-later-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06972498/estudio-multicentrico-prospectivo-ivosimab-quimioterapia-como-tratamiento-neoadyuvante-para-metastasis-hepaticas-de-crc-pmmr-mss-resecable 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/a-prospective-multicenter-study-ivosimab-chemotherapy-as-neoadjuvant-for-resectable-pmmr-mss-crc-liver-mets 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07255664/un-ensayo-de-fase-i-iia-fih-que-evalua-la-viabilidad-de-la-administracion-de-inmunoterapia-basada-en-til-en-pacientes-con-crc-metastasico-y-cancer-de-pancreas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07255664/a-fih-phase-i-iia-trial-assessing-feasibility-of-administrations-of-til-based-immunotherapy-in-patients-with-metastatic-crc-and-pc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06435689/estudio-y-modulacion-de-las-respuestas-inmunitarias-en-los-canceres-colorrectales-primarios-y-metastasicos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-en-combinacion-con-fianlimab-para-el-cancer-colorrectal-no-metastasico-que-puede-ser-extirpado-quirurgicamente 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-with-fianlimab-for-resectable-non-metastatic-colon-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/tratamiento-antitumoral-sistemico-con-o-sin-quimioterapia-en-aerosol-intraabdominal-a-presion-para-metastasis-peritoneales-de-cancer-de-colon-pipox02 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/systemic-antitumor-treatment-with-or-without-pressurized-intraperitoneal-aerosol-chemotherapy-for-colon-peritoneal-metastases-pipox02 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01762813/evaluacion-de-los-resultados-clinicamente-relevantes-y-analisis-de-biomarcadores-para-su-integracion-traslacional-en-el-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/assessment-of-clinically-related-outcomes-and-biomarker-analysis-for-translational-integration-in-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05167448/un-estudio-de-es104-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167448/a-study-of-es104-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparolimab-tuvonralimab-en-combinacion-con-bevacizumab-y-capeox-como-terapia-de-conversion-para-metastasis-hepaticas-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparomlimab-tuvonralimab-combined-with-bevacizumab-and-capeox-as-conversion-therapy-for-colorectal-cancer-liver-metastasis 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-en-combinacion-con-cetuximab-y-quimioterapia-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-con-ras-braf-de-tipo-salvaje 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-in-combination-with-cetuximab-and-chemotherapy-as-first-line-treatment-for-ras-braf-wild-type-advanced-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-un-estudio-para-obtener-mas-informacion-sobre-el-farmaco-de-estudio-denominado-pf-08634404-en-combinacion-con-quimioterapia-en-participantes-adultos-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/estudio-abierto-con-bbo-10203-en-pacientes-con-tumores-solidos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/open-label-study-of-bbo-10203-in-subjects-with-advanced-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621159/un-estudio-de-fase-ib-ii-de-hdm2017-en-combinacion-con-el-tratamiento-estandar-en-el-cancer-colorrectal-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621159/a-phase-ib-ii-study-of-hdm2017-in-combination-with-standard-of-care-in-advanced-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509398/fmt-en-combinacion-con-la-terapia-estandar-de-primera-linea-en-el-cancer-colorrectal-inicialmente-irresecable 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509398/fmt-combined-with-standard-first-line-therapy-in-initially-unresectable-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico-refractario-a-las-quimioterapias-estandar-en-corea-del-sur-first-k 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapies-in-south-korea-patients-first-k 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-la-terapia-de-conversion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-plus-targeted-therapy-for-first-line-conversion-therapy-of-colorectal-cancer-liver-metastases 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-en-combinacion-con-trifluridina-tipiracil-en-el-tratamiento-del-cancer-colorrectal-metastasico-refractario 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-combined-with-trifluridine-tipiracil-in-the-treatment-of-refractory-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662786/un-estudio-de-amivantamab-y-mfolfox6-o-folfiri-frente-a-cetuximab-y-mfolfox6-o-folfiri-como-tratamiento-de-primera-linea-en-participantes-con-cancer-colorrectal-irresecable-o-metastasico-del-lado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/a-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-cetuximab-and-mfolfox6-or-folfiri-as-first-line-treatment-in-participants-with-kras-nras-and-braf-wild-type-unresectable-or-metastatic-left-sided 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomida-y-bevacizumab-para-el-cancer-colorrectal-metastasico-con-metilacion-del-gen-mgmt-y-estabilidad-de-microsatelites 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomide-and-bevacizumab-for-mgmt-silenced-microsatellite-stable-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06522919/tratamiento-secuencial-con-inmunoterapia-y-quimioterapia-que-consiste-en-la-administracion-de-pembrolizumab-mas-vacuna-de-celulas-dendriticas-seguido-de-trifluridina-tipiracil-mas-bevacizumab-en 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06522919/sequential-immunochemotherapy-treatment-with-pembrolizumab-plus-dendritic-cell-dc-vaccine-followed-by-trifluridine-tipiracil-plus-bevacizumab-in-refractory-mismatch-repair-proficient-pmmr-or 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06106308/estudio-de-onvansertib-en-combinacion-con-folfiri-y-bevacizumab-o-folfox-y-bevacizumab-en-comparacion-con-folfiri-y-bevacizumab-o-folfox-y-bevacizumab-para-el-tratamiento-de-primera-linea-del-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06106308/study-of-onvansertib-in-combination-with-folfiri-and-bevacizumab-or-folfox-and-bevacizumab-versus-folfiri-and-bevacizumab-or-folfox-and-bevacizumab-for-first-line-treatment-of-metastatic-colorectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/un-estudio-que-evalua-los-eventos-adversos-y-la-actividad-de-la-enfermedad-al-comparar-la-administracion-intravenosa-iv-de-abbv-400-con-los-comprimidos-orales-de-trifluridina-y-tipiracil-lonsurf-mas 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/a-study-assessing-adverse-events-and-disease-activity-of-intravenously-iv-infused-telisotuzumab-adizutecan-in-adult-participants-with-c-met-protein-above-cutoff-level-above-refractory-metastatic 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06934018/efecto-del-ancho-del-margen-quirurgico-en-la-recurrencia-y-la-supervivencia-en-pacientes-con-oligometastasis-hepatica-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/effect-of-surgical-margin-width-on-recurrence-and-survival-in-patients-with-hepatic-oligometastasis-of-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04224779/biopsias-liquidas-e-imagenologia-para-mejorar-la-atencion-oncologica 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/liquid-biopsies-and-imaging-for-improved-cancer-care 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06543836/tratamiento-guiado-por-ctdna-con-tki-mas-inhibidor-de-pd-1-en-el-cancer-colorrectal-avanzado-pmmr-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/ctdna-guided-treatment-of-tki-plus-pd-1-inhibitor-for-advanced-pmmr-mss-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/tratamiento-local-hepatico-para-metastasis-de-cancer-colorrectal-multiorganico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/local-liver-treatment-for-multi-organ-colorectal-cancer-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-un-ensayo-clinico-que-evalua-los-efectos-de-la-aspirina-sobre-la-recurrencia-de-la-enfermedad-y-la-supervivencia-tras-la-terapia-primaria-en-tumores-solidos-no-metastasicos-comunes 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-a-trial-assessing-the-effects-of-aspirin-on-disease-recurrence-and-survival-after-primary-therapy-in-common-non-metastatic-solid-tumours 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06012734/lb-100-inhibidor-de-pp2a-y-atezolizumab-inhibidor-de-pd-l1-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06012734/lb-100-pp2a-inhibitor-and-atezolizumab-pd-l1-inhibitor-in-metastatic-colorectal-cancer-patients 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06958419/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-linfaticos-combinada-con-quimioterapia-bevacizumab-e-inhibidor-de-pd-1-en-cancer-colorrectal-metastasico-pmmr-mss-modifi-crc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06958419/node-sparing-short-course-radiotherapy-plus-chemotherapy-bevacizumab-and-pd-1-inhibitor-in-metastatic-pmmr-mss-colorectal-cancer-modifi-crc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614751/dat-2645-un-inhibidor-de-parg-como-monoterapia-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-que-presenten-alteraciones-de-perdida-de-funcion-en-brca1-2-y-o-otros-defectos-en-la-via-de 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/a-parg-inhibitor-dat-2645-monotherapy-in-patients-with-advanced-metastatic-solid-tumors-harboring-brca1-2-loss-of-function-alterations-and-or-other-defects-in-the-ddr-pathway 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/estudio-retrospectivo-multicentrico-sobre-la-optimizacion-de-las-estrategias-de-inmunoterapia-combinada-en-el-cancer-colorrectal-avanzado-mss-msi-l-pmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/multicenter-retrospective-study-on-optimizing-combination-immunotherapy-strategies-in-mss-msi-l-pmmr-advanced-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06590259/un-estudio-sobre-la-eficacia-y-la-seguridad-de-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-el-tratamiento-de-la-crclm 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07004413/cetuximab-en-administracion-continua-o-intermitente-combinado-con-folfiri-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-ras-braf-tipo-salvaje 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/continuous-or-intermittent-cetuximab-plus-folfiri-as-first-line-treatment-in-ras-braf-wild-type-mcrc-patients 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07353268/estudio-de-fase-ib-ii-de-ql1706-fruquintinib-terapia-de-radiacion-concurrente-scrt-frente-a-la-terapia-estandar-de-tercera-linea-en-cancer-colorrectal-irresecable-con-metastasis-hepaticas-y-estado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07353268/phase-ib-ii-study-of-ql1706-fruquintinib-scrt-vs-standard-third-line-therapy-in-unresectable-liver-metastatic-pmmr-mss-colorectal-cancer-safety-tolerability-and-efficacy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/radioterapia-estereotactica-ablativa-sbrt-de-metastasis-tras-el-tratamiento-neoadyuvante-para-el-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/sbrt-of-metastases-following-neo-adjuvant-treatment-for-colorectal-cancer-with-synchronous-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnostico-de-multiples-tipos-de-cancer-y-seguimiento-de-tumores-residuales-minimos-tras-el-tratamiento-mediante-el-analisis-de-sangre-y-tecnicas-geneticas-de-alta-sensibilidad 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnosis-of-multiple-cancer-and-monitoring-of-minimal-residual-tumors-after-treatment-using-blood-and-high-sensitivity-genetic-analysis-techniques 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-en-combinacion-con-fruquintinib-y-radioterapia-estereotactica-ablativa-sbrt-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores-en-pacientes-con-crc-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-combined-with-fruquintinib-and-sbrt-as-athird-line-and-posterior-line-treatment-in-patients-with-mss-crc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analisis-de-la-dinamica-de-pd-l1-tmb-msi-y-ctdna-para-predecir-y-monitorizar-la-respuesta-a-la-inmunoterapia-en-el-cancer-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-y-pirfenidona-en-combinacion-con-un-anticuerpo-anti-pd-1-en-el-tratamiento-del-carcinoma-colorrectal-avanzado-o-metastasico-pmmr-mss 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-and-pirfenidone-in-combination-with-anti-pd-1-antibody-in-advanced-or-metastatic-pmmr-mss-colorectal-carcinoma 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07550088/bal-bot-agent-797-en-crc-con-pmmr-y-metastasis-hepaticas 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07550088/bal-bot-agent-797-in-pmmr-crc-with-liver-metastases 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparacion-de-la-pet-rm-con-68ga-ga-ctr-fapi-y-18f-fdg-para-la-estadificacion-de-los-ganglios-linfaticos-en-el-cancer-de-recto 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparison-of-68ga-ga-ctr-fapi-and-18f-fdg-pet-mri-for-lymph-node-staging-in-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06185556/ensayo-coldfire-iii-eficacia-de-la-electroforesis-irreversible-y-la-radioterapia-estereotactica-corporal-en-metastasis-hepaticas-de-cancer-colorrectal-perivasculares-y-peribiliares 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06185556/coldfire-iii-trial-efficacy-of-irreversible-electroporation-and-stereotactic-body-radiotherapy-for-perivascular-and-peribiliary-colorectal-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07559760/nueva-terapia-combinada-de-segunda-linea-para-el-cancer-colorrectal-metastasico-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07559760/new-second-line-combo-therapy-for-mss-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381309/virus-oncolitico-h101-radioterapia-estereotactica-ablativa-sbrt-quimioterapia-terapia-dirigida-inmunoterapia-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381309/oncolytic-virus-h101-sbrt-chemotherapy-targeted-therapy-immunotherapy-for-unresectable-crlm 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03711110/estrategias-de-prevencion-cardiovascular-en-pacientes-oncologicos-de-edad-avanzada-ensayo-clinico-cartier 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03711110/cardiovascular-prevention-strategies-in-elderly-patients-with-cancer-cartier-clinical-trial 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06199232/tratamiento-dirigido-mas-tislelizumab-y-haic-para-el-cancer-colorrectal-metastasico-crclm-en-estadio-avanzado-que-no-ha-respondido-al-tratamiento-sistemico-estandar 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06199232/targeted-treatment-plus-tislelizumab-and-haic-for-advanced-crclm-failed-from-standard-systemic-treatment 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07011576/un-estudio-de-fruquintinib-mas-folfiri-como-tratamiento-de-segunda-linea-para-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07011576/a-study-of-fruquintinib-plus-folfiri-as-second-line-treatment-for-participants-with-metastatic-colorectal-cancer-fruitful 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/vacuna-contra-el-cancer-con-celulas-tumorales-completas-tanto-autologa-como-alogenica-para-tumores-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/autologous-and-allogeneic-whole-cell-cancer-vaccine-for-metastatic-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06496919/investigacion-en-el-mundo-real-sobre-la-prevencion-y-el-tratamiento-de-la-metastasis-peritoneal-y-la-ascitis-maligna-mediante-la-infusion-intraperitoneal-de-rmhtnf-en-tumores-malignos-gastricos-y 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06496919/a-real-world-research-on-the-prevention-and-treatment-of-peritoneal-metastasis-and-malignant-ascites-by-intraperitoneal-infusion-of-rmhtnf-in-gastric-and-colorectal-malignant-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/deteccion-mediante-biomarcadores-sanguineos-en-el-cribado-de-cpc-impulsado-por-el-vph 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/blood-biomarkers-based-screening-for-hpv-driven-opc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/un-estudio-que-evalua-el-farmaco-fmc-376-en-participantes-con-tumores-solidos-que-presentan-la-mutacion-kras-g12c 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/a-study-evaluating-fmc-376-in-participants-with-kras-g12c-mutated-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/oxaliplatino-sistemico-o-quimioterapia-intraarterial-combinada-con-lv5fu2-irinotecan-y-una-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-restringido-al-higado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/systemic-oxaliplatin-or-intra-arterial-chemotherapy-combined-with-lv5fu2-irinotecan-and-an-target-therapy-in-first-line-treatment-of-metastatic-colorectal-cancer-restricted-to-the-liver 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07229846/un-estudio-clinico-de-fase-ii-de-un-solo-brazo-y-en-un-solo-centro-para-evaluar-aipalolitovorelizumab-ql1706-en-combinacion-con-bevacizumab-y-quimioterapia-estandar-como-tratamiento-de-primera-linea 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229846/a-single-arm-single-center-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-bevacizumab-and-standard-chemotherapy-as-first-line-treatment-for-mss-pmmr-metastatic-colorectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06412198/un-estudio-multicentrico-de-fase-1b-2-con-adagrasib-cetuximab-y-cemiplimab-para-el-cancer-colorrectal-metastasico-que-presenta-mutaciones-kras-g12c 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/a-multicenter-phase-1b-2-study-of-adagrasib-cetuximab-and-cemiplimab-for-metastatic-colorectal-cancer-harboring-kras-g12c-mutations 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-con-metastasis-hepaticas 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-combined-with-pd-1-in-liver-metastasis-colorectal-cancer-patients 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02886104/comparacion-de-la-hepatectomia-y-la-ablacion-local-para-el-tratamiento-de-metastasis-hepaticas-sincronicas-y-metacronicas-resecables-del-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparison-of-hepatectomy-and-local-ablation-for-resectable-synchronous-and-metachronous-colorectal-liver-metastasis 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-y-toripalimab-en-un-estudio-de-cancer-colorrectal-derecho-ultra-seleccionado-con-mutaciones-ras-braf-de-tipo-salvaje 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-toripalimab-in-ras-braf-wild-type-ultraselected-right-sided-colorectal-cancer-study 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/radioembolizacion-preoperatoria-con-y-90-para-el-control-tumoral-y-la-hipertrofia-del-futuro-remanente-hepatico-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/imagenes-moleculares-con-fapi-para-el-diagnostico-del-subtipo-desfavorable-cms4-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/fapi-molecular-imaging-for-diagnosis-of-the-cms4-unfavorable-colorectal-cancer-subtype 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/inmunoterapia-con-linfocitos-infiltrantes-tumorales-para-pacientes-con-cancer-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-en-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-cancer-colorrectal-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-alone-and-in-combination-with-pembrolizumab-in-patients-with-colorectal-cancer-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-en-combinacion-con-quimioterapia-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-mutacion-en-ras-o-con-metastasis-en-el-lado-derecho-y-con 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-combined-with-chemotherapy-and-bevacizumab-as-first-line-treatment-for-ras-mutated-or-right-sided-metastatic-mss-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/un-estudio-de-fase-i-para-evaluar-tgi-6-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/a-phase-1-study-to-evaluate-tgi-6-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-con-o-sin-ipilimumab-en-el-tratamiento-de-pacientes-con-cancer-metastasico-del-conducto-anal-refractario 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-with-or-without-ipilimumab-in-treating-patients-with-refractory-metastatic-anal-canal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959550/estudio-de-fase-ii-del-anticuerpo-biespecifico-anti-pd-1-vegf-ivonescimab-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/phase-ii-study-of-anti-pd-1-vegf-bispecific-antibody-ivonescimab-in-patients-with-previously-treated-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-solo-o-en-combinacion-con-radioterapia-hipofraccionada-de-baja-dosis-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-alone-or-in-combination-with-hypofractionated-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/efecto-de-la-microbiota-intestinal-y-sus-metabolitos-en-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulacion-de-la-microbiota-intestinal-mediante-una-dieta-preoperatoria-estandarizada-para-prevenir-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-tras-la-cirugia 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulation-of-the-gut-microbiome-by-a-standardized-preoperative-diet-to-prevent-colorectal-cancer-recurrence-and-metastasis-following-surgery 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/un-estudio-de-gsk5764227-en-combinacion-con-el-tratamiento-estandar-soc-u-otros-agentes-en-participantes-con-tumores-solidos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/terapia-con-linfocitos-infiltrantes-tumorales-mediante-inmunoterapia-para-el-cancer-de-colon-y-recto 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/biological-tumor-infiltrating-lymphocytes-therapy-with-immunotherapy-for-colon-and-rectum-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-en-pacientes-con-carcinoma-colorrectal-metastasico-de-diagnostico-reciente 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-in-newly-diagnosed-metastatic-colorectal-carcinoma 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03635021/estudio-para-evaluar-la-eficacia-de-folfox-panitumumab-seguido-de-folfiri-bevacizumab-secuencia-1-frente-a-folfox-bevacizumab-seguido-de-folfiri-panitumumab-secuencia-2-en-pacientes-no-tratados-con 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03635021/study-to-evaluate-the-efficacy-of-folfox-panitumumab-followed-by-folfiri-bevacizumab-sequence-1-versus-folfox-bevacizumab-followed-by-folfiri-panitumumab-sequence-2-in-untreated-patients-with-wild 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/desescalada-o-cambio-de-tratamiento-segun-la-variacion-del-adn-tumoral-circulante-tras-2-ciclos-de-quimioterapia-combinada-mas-terapia-dirigida-en-el-cancer-colorrectal-metastasico-irresecable 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/de-scalation-or-switch-of-treatment-according-to-circulating-tumor-dna-variation-after-2-cycles-of-doublet-chemotherapy-plus-targeted-agent-in-metastatic-unresectable-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07204574/estudio-de-fase-1b-iia-abierto-de-escalada-y-expansion-de-dosis-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-preliminar-de-la-combinacion-de-hcb101-cetuximab-bevacizumab-y-folfox-folfiri 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07204574/the-phase-1b-iia-open-label-dose-escalation-and-dose-expansion-to-evaluate-safety-tolerability-and-preliminary-efficacy-of-the-combination-of-hcb101-cetuximab-bevacizumab-and-folfox-folfiri-in 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04294264/tas-102-y-oxaliplatino-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv-refractario 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04294264/tas-102-and-oxaliplatin-for-the-treatment-of-refractory-stage-iv-colon-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06275958/estudio-de-dosis-quimioterapia-con-dosis-reducidas-en-primera-linea-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/dosage-study-upfront-dose-reduced-chemotherapy-in-older-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06883084/relevancia-clinica-de-la-regresion-patologica-en-los-ganglios-linfaticos-en-el-cancer-colorrectal-localmente-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06883084/clinical-relevance-of-pathologic-regression-in-lymph-node-for-locally-advanced-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05240950/celulas-car-t-anti-cea-para-el-tratamiento-de-metastasis-hepaticas-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/anti-cea-car-t-cells-to-treat-colorectal-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854668/un-estudio-de-la-combinacion-de-anlotinib-clorhidrato-en-capsulas-con-quimioterapia-como-tratamiento-de-primera-linea-en-sujetos-con-cancer-colorrectal-metastasico-ras-braf-tipo-salvaje 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854668/a-study-of-anlotinib-hydrochloride-capsule-combined-with-chemotherapy-as-first-line-treatment-in-subjects-with-ras-braf-wild-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04157322/marcadores-plasmaticos-de-5hmc-como-indicador-de-metastasis-peritoneal-en-cancer-colorrectal-apendicular 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04157322/plasma-5hmc-signatures-as-a-marker-of-colorectal-appendiceal-peritoneal-metastasis 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/un-estudio-de-nivolumab-nivolumab-mas-ipilimumab-o-quimioterapia-a-eleccion-del-investigador-para-el-tratamiento-de-participantes-con-cancer-colorrectal-metastasico-mcrc-con-deficiencia-en-la 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/a-study-of-nivolumab-nivolumab-plus-ipilimumab-or-investigator-s-choice-chemotherapy-for-the-treatment-of-participants-with-deficient-mismatch-repair-dmmr-microsatellite-instability-high-msi-h 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07202364/un-estudio-de-yl202-en-pacientes-con-tumores-solidos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/a-study-of-yl202-in-patients-with-advanced-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/panitumumab-administrado-de-forma-intermitente-o-continua-en-combinacion-con-folfiri-para-el-cancer-colorrectal-metastasico-de-lado-izquierdo-con-mutaciones-ras-b-raf-de-tipo-salvaje 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/intermittent-or-continuous-panitumumab-plus-folfiri-for-left-sided-ras-b-raf-wild-type-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/quimioterapia-post-reseccion-ablacion-en-pacientes-con-cancer-colorrectal-metastasico-fire-9-port-aio-krk-0418 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/post-resection-ablation-chemotherapy-in-patients-with-metastatic-colorectal-cancer-fire-9-port-aio-krk-0418 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/un-estudio-para-obtener-mas-informacion-sobre-la-eficacia-y-la-seguridad-del-tratamiento-con-tabletas-de-sevabertinib-bay-2927088-en-participantes-que-tienen-un-tumor-solido-con-mutaciones-del 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/a-study-to-learn-more-about-how-well-treatment-with-sevabertinib-bay-2927088-tablets-works-and-how-safe-it-is-in-participants-who-have-a-solid-tumor-with-mutations-of-the-human-epidermal-growth 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-en-combinacion-en-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-en-estadio-iv-resistente-al-tratamiento-y-en-otros-canceres-metastasicos-del 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-combination-in-stage-iv-refractory-pmmr-mss-crc-and-other-metastatic-gi-cancers 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/eficacia-y-seguridad-de-folfox-cetuximab-frente-a-folfoxiri-bevacizumab-ambos-en-combinacion-con-ql1706-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-mcrc-localizado-en-el 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/efficacy-and-safety-of-folfox-cetuximab-vs-folfoxiri-bevacizumab-both-with-ql1706-in-first-line-treatment-of-left-sided-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03740503/investigacion-genomica-de-pacientes-con-respuestas-inusuales 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/genomic-investigation-of-unusual-responders 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04449874/un-estudio-para-evaluar-la-seguridad-la-farmacocinetica-y-la-actividad-de-gdc-6036-en-monoterapia-o-en-combinacion-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-con-una-mutacion-kras 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04449874/a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-gdc-6036-alone-or-in-combination-in-participants-with-advanced-or-metastatic-solid-tumors-with-a-kras-g12c-mutation 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07085091/un-estudio-de-fase-i-en-humanos-con-alx2004-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-seleccionados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03829462/evaluacion-de-la-combinacion-de-regorafenib-e-irinotecan-frente-a-regorafenib-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03829462/assessing-a-regorafenib-irinotecan-combination-versus-regorafenib-alone-in-metastatic-colorectal-cancer-patients 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/un-estudio-clinico-de-fase-ii-de-aipalolitovorelizumab-ql1706-en-combinacion-con-fruquintinib-para-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-inmunodominante-que-ha-mostrado-falta-de 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/a-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-fruquintinib-in-the-treatment-of-immunodominant-pmmr-mss-metastatic-colorectal-cancer-that-has-failed-second-line-or-above 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-de-cancer-colorrectal-metastasico-irresecable-a-resecable 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-from-unresectable-to-resectable-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05107674/un-estudio-de-nx-1607-en-adultos-con-tumores-malignos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/a-study-of-nx-1607-in-adults-with-advanced-malignancies 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/un-estudio-de-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/a-study-of-botensilimab-and-balstilimab-for-the-treatment-of-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04329494/pipac-para-el-tratamiento-de-la-carcinomatosis-peritoneal-en-pacientes-con-cancer-de-ovario-utero-apendice-colon-o-estomago 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04329494/pipac-for-the-treatment-of-peritoneal-carcinomatosis-in-patients-with-ovarian-uterine-appendiceal-colorectal-or-gastric-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/estudio-de-fase-iii-sobre-el-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-que-no-son-candidatos-para-recibir-terapia-intensiva 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/phase-iii-study-in-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-who-are-not-candidate-for-intensive-therapy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/estudio-observacional-sobre-la-combinacion-de-fluoropirimidina-y-bevacizumab-en-pacientes-con-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/observational-study-regarding-the-combination-of-fluoropyrimidine-and-bevacizumab-in-patients-with-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06464692/estudio-para-evaluar-los-eventos-adversos-y-como-el-telisotuzumab-adizutecan-abbv-400-administrado-por-via-intravenosa-iv-se-distribuye-por-el-organismo-de-los-participantes-adultos-con-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/study-to-assess-adverse-events-and-how-intravenously-iv-infused-telisotuzumab-adizutecan-abbv-400-moves-through-the-body-of-adult-participants-with-unresectable-locally-advanced-metastatic-colorectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/estudio-de-la-terapia-car-t-dirigida-contra-el-cea-ptc13-en-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridina-tipiracil-mas-regorafenib-frente-a-trifluridina-tipiracil-mas-bevacizumab-para-el-cancer-colorrectal-metastasico-refractario 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridine-tipiracil-plus-regorafenib-vs-trifluridine-tipiracil-plus-bevacizumab-for-refractory-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07178717/un-estudio-para-caracterizar-el-uso-de-encorafenib-mas-cetuximab-como-tratamiento-de-reintroduccion-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-tras-una-terapia-previa-con 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178717/a-study-to-characterize-encorafenib-plus-cetuximab-as-rechallenge-treatment-for-braf-v600e-mutant-metastatic-colorectal-cancer-patients-after-previous-therapy-with-braf-inhibitors-based-combinations 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621497/folfox8-frente-a-mfolfox6-con-bevacizumab-o-cetuximab-para-el-cancer-colorrectal-metastasico-irresecable-en-primera-linea-fase-ii 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-versus-mfolfox6-with-bevacizumab-or-cetuximab-for-first-line-unresectable-metastatic-colorectal-cancer-phase-ii 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-y-panitumumab-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-and-panitumumab-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224724/deteccion-de-metastasis-extrahepaticas-derivadas-de-exosomas-mediante-biopsia-liquida-en-metastasis-hepaticas-del-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787197/ctdna-en-pacientes-con-crc-sometidos-a-cirugia-con-intencion-curativa-para-metastasis-hepaticas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787197/ctdna-in-crc-patients-undergoing-curative-intent-surgery-for-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/un-estudio-de-amivantamab-y-folfiri-frente-a-cetuximab-bevacizumab-y-folfiri-en-participantes-con-cancer-colorrectal-kras-nras-y-braf-de-tipo-salvaje-que-previamente-han-recibido-quimioterapia 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-and-folfiri-in-participants-with-kras-nras-and-braf-wild-type-colorectal-cancer-who-have-previously-received-chemotherapy 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/estudio-de-resultados-informados-por-el-paciente-mediante-un-sistema-de-monitorizacion-electronica-para-cancer-solido-avanzado-o-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/patient-reported-outcomes-study-using-electronic-monitoring-system-for-advanced-or-metastatic-solid-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-serplulimab-in-patients-with-metastatic-colorectal-cancer-undergoing-cytoreductive-surgery-a-single-arm-single 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06992258/un-ensayo-aleatorizado-de-fase-ii-que-compara-fruquintinib-y-tas-102-con-fruquintinib-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-refractario 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992258/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compared-to-fruquintinib-in-patients-with-refractory-advanced-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03303495/un-estudio-comparativo-de-folfiri-en-segunda-linea-bevacizumab-frente-a-irinotecan-bevacizumab-en-pacientes-con-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/a-study-of-2nd-line-folfiri-bevacizumab-vs-irinotecan-bevacizumab-in-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07631884/estudio-exploratorio-sobre-la-eficacia-y-la-seguridad-del-trastuzumab-rezetecan-en-el-tratamiento-de-tumores-solidos-avanzados-con-expresion-de-her2 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/exploratory-study-on-the-efficacy-and-safety-of-trastuzumab-rezetecan-in-the-treatment-of-her2-expressiong-advanced-solid-tumor 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/estudio-de-fruquintinib-en-combinacion-con-tegafur-gimeracil-y-oteracil-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06126419/aplicacion-de-la-terapia-con-insulina-en-dosis-altas-para-mejorar-la-funcion-y-regeneracion-hepatica 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/ensayo-clinico-de-una-terapia-basada-en-5-fluorouracilo-5-fu-en-combinacion-con-fruquintinib-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable-o-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-fruquintinib-in-patients-with-locally-advanced-unresectable-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracilo-leucovorina-5fu-lv-en-combinacion-con-regorafenib-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/radioterapia-ultrafraccionada-guiada-por-cga-y-tratamiento-sistemico-de-primera-linea-en-pacientes-ancianos-o-fragiles-con-cmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/cga-guided-ultrafractionated-rt-and-first-line-systemic-treatment-in-elderly-or-frail-patients-with-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007767/evaluacion-de-sintilimab-bevacizumab-decitabina-para-el-cancer-colorrectal-avanzado-pmmr-mss-tras-dos-o-mas-tratamientos-previos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007767/exploring-sintilimab-bevacizumab-decitabine-for-advanced-pmmr-mss-colorectal-cancer-after-2-prior-therapies 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980532/glumetinib-en-combinacion-con-fruquintinib-en-el-tratamiento-de-la-amplificacion-de-met-o-la-sobreexpresion-de-la-proteina-en-el-cancer-colorrectal-metastasico-irresecable-en-tercera-linea-de 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980532/glumetinib-combined-with-fruquintinib-in-the-treatment-of-met-amplification-or-protein-overexpression-in-third-line-unresectable-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03803553/identificacion-y-tratamiento-de-la-enfermedad-micrometastasica-en-el-cancer-de-colon-en-estadio-iii 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03803553/identification-and-treatment-of-micrometastatic-disease-in-stage-iii-colon-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595931/m6620-e-hidrocloruro-de-irinotecan-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-mediante-cirugia 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-and-irinotecan-hydrochloride-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/metastasis-pulmonares-de-cancer-colorrectal-metastasis-pulmonar-versus-radioterapia-ablativa-estereotactica 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-plus-mfolfoxiri-as-first-line-treatment-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-y-pembrolizumab-en-el-tratamiento-de-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-and-pembrolizumab-in-treating-participants-with-advanced-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/un-estudio-exploratorio-de-la-sensibilidad-al-tratamiento-y-los-factores-pronosticos-en-un-estudio-de-eficacia-y-seguridad-de-mfolfox6-bevacizumab-frente-a-mfolfox6-panitumumab-en-pacientes-con 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/an-exploratory-study-of-treatment-sensitivity-and-prognostic-factors-in-a-efficacy-and-safety-study-of-mfolfox6-bevacizumab-versus-mfolfox6-panitumumab-therapy-in-patients-with-chemotherapy-naive 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/ensayo-clinico-prospectivo-de-seguridad-y-eficacia-sobre-la-terapia-con-aerosol-intraperitoneal-presurizado-para-la-metastasis-peritoneal-del-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/a-prospective-safety-and-efficacy-clinical-trial-of-pressurized-intraperitoneal-aerosol-therapy-for-peritoneal-metastasis-of-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-combinado-con-quimioterapias-a-dosis-bajas-y-aspirina-seguido-de-quimioterapias-estandar-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-with-low-dose-chemotherapies-and-aspirin-followed-by-standard-chemotherapies-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03451370/tratamiento-de-primera-linea-con-la-combinacion-de-capecitabina-y-oxaliplatino-mas-bevacizumab-en-pacientes-ancianos-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03451370/first-line-combination-of-capecitabine-and-oxaliplatin-plus-bevacizumab-in-elderly-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07540572/un-estudio-para-investigar-la-seguridad-la-farmacocinetica-y-la-eficacia-preliminar-de-la-terapia-con-ide574-en-participantes-adultos-con-tumores-solidos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07540572/a-study-to-investigate-the-safety-pharmacokinetics-and-preliminary-efficacy-of-ide574-therapy-in-adult-participants-with-advanced-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543471/un-estudio-de-fase-i-multicentrico-aleatorizado-doble-ciego-y-controlado-en-paralelo-que-compara-hlx05-n-con-erbitux-r-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/a-phase-i-multicentre-randomized-double-blind-parallel-controlled-study-of-hlx05-n-vs-erbitux-r-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129787/ablacion-frente-a-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129787/ablation-vs-resection-of-colorectal-cancer-liver-metastases 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543744/un-estudio-comparativo-de-la-farmacocinetica-la-seguridad-y-la-inmunogenicidad-de-rph-030-y-vectibix-r-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-de-tipo-salvaje-como-terapia-de-primera 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543744/a-comparative-study-of-pharmacokinetics-safety-and-immunogenicity-of-rph-030-and-vectibix-r-in-patients-with-metastatic-colorectal-cancer-with-wild-type-ras-as-first-line-therapy-in-combination-with 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787587/un-estudio-del-inhibidor-de-parg-ide161-en-participantes-con-tumores-solidos-avanzados 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05787587/a-study-of-parg-inhibitor-ide161-in-participants-with-advanced-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/un-estudio-de-precemtabart-tocentecan-con-o-sin-bevacizumab-en-comparacion-con-trifluridina-tipiracil-mas-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-previamente-tratado-proceade 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-compared-to-trifluridine-tipiracil-plus-bevacizumab-in-participants-with-previously-treated-metastatic-colorectal-cancer-proceade-crc-03 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/un-estudio-de-fase-ib-iii-de-suvemcitug-mas-ftd-tpi-en-participantes-con-cancer-colorrectal-metastasico-refractario 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/a-phase-ib-iii-study-of-suvemcitug-plus-ftd-tpi-in-participants-with-refractory-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07261709/trifluridina-tipiracil-mas-fruquintinib-frente-a-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-refractario-un-ensayo-aleatorizado-controlado-de-etiqueta-abierta-de-no 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridine-tipiracil-plus-fruquintinib-vs-trifluridine-tipiracil-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-controlled-open-label-non-inferiority-trial 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553572/aplicacion-digital-para-la-monitorizacion-remota-y-el-manejo-de-los-sintomas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/remote-monitoring-and-symptom-management-digital-application 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/trifluridina-tipiracil-a-dosis-bajas-con-bevacizumab-en-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/low-dose-trifluridine-tipiracil-with-bevacizumab-in-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07364656/analisis-de-la-presencia-y-los-efectos-sobre-la-funcion-cardiaca-de-los-autoanticuerpos-anti-nav1-5-en-pacientes-con-tumores-metastasicos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav1-5-autoantibodies-in-patients-with-metastatic-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazina-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazine-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsia-mas-quimioterapia-frente-a-quimioterapia-sola-en-metastasis-hepaticas-avanzadas-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsy-plus-chemotherapy-vs-chemotherapy-alone-for-advanced-colorectal-liver-metastasis 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/estudio-prospectivo-multicentrico-a-nivel-nacional-para-evaluar-los-factores-pronosticos-relacionados-con-la-eficacia-del-tratamiento-con-fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/prospective-national-cohort-evaluating-prognostic-factors-for-efficacy-of-fruquintinib-treatment-in-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04845490/estudio-comparativo-de-mitomicina-y-lobaplatino-en-pacientes-con-cancer-colorrectal-avanzado-sometidos-a-cirugia-radical-combinada-con-quimioterapia-intraperitoneal-hiperermica 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06043466/un-ensayo-clinico-dirigido-a-las-celulas-t-con-receptor-quimerico-de-antigeno-car-t-contra-el-antigeno-cea-para-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06043466/a-clinical-trial-targeting-cea-chimeric-antigen-receptor-t-car-t-for-cea-positive-advanced-malignant-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/tratamiento-de-mantenimiento-con-tislelizumab-y-capecitabina-para-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/maintenance-tislelizumab-capecitabine-to-treat-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03485209/estudio-de-eficacia-y-seguridad-de-tisotumab-vedotina-en-pacientes-con-tumores-solidos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/efficacy-and-safety-study-of-tisotumab-vedotin-for-patients-with-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05489211/estudio-de-dato-dxd-como-monoterapia-y-en-combinacion-con-agentes-antineoplasicos-en-pacientes-con-tumores-solidos-avanzados-tropion-pantumor03 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07392567/validacion-prospectiva-de-un-modelo-de-inteligencia-artificial-para-predecir-la-metastasis-hepatica-en-el-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/prospective-validation-of-an-ai-model-for-predicting-liver-metastasis-in-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-en-combinacion-con-sintilimab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-avanzado-excluyendo-las-metastasis-hepaticas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-combined-with-sintilimab-as-first-line-treatment-for-advanced-non-liver-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-mas-irinotecan-en-pacientes-con-cancer-colorrectal-metastasico-con-tipo-salvaje-de-neoras-en-terapia-de-tercera-linea 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-plus-irinotecan-in-patients-with-neoras-wild-type-metastatic-colorectal-cancer-in-third-line-therapy 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07583381/un-estudio-prospectivo-sobre-una-tecnologia-de-estimacion-de-la-presion-asistida-por-subarmonicos-para-la-prediccion-temprana-de-la-respuesta-a-la-terapia-sistemica-en-metastasis-hepaticas-del-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-en-combinacion-con-terapia-de-mantenimiento-para-la-prevencion-de-la-recurrencia-postoperatoria-en-cancer-colorrectal-con-metastasis-peritoneales 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-combined-with-maintenance-therapy-for-prevention-of-postoperative-recurrence-in-peritoneal-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04607421/un-estudio-de-encorafenib-mas-cetuximab-con-o-sin-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/a-study-of-encorafenib-plus-cetuximab-with-or-without-chemotherapy-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04491929/terapia-de-radiacion-interna-selectiva-con-microesferas-de-resina-de-90y-para-metastasis-hepaticas-de-cancer-colorrectal-refractario 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/selective-internal-radiation-therapy-with-90y-resin-micropheres-for-refractory-colorectal-cancer-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07076823/seguridad-y-eficacia-de-canagliflozina-en-pacientes-con-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-msi-h 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07076823/safety-and-efficacy-of-canagliflozin-in-patients-with-metastatic-high-microsatellite-instability-msi-h-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-en-combinacion-con-tas-102-y-bevacizumab-en-el-cancer-colorrectal-recurrente-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-in-combination-with-tas-102-and-bevacizumab-in-recurrent-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05296681/producto-microbiano-para-promover-la-salud-del-microbioma-y-mejorar-la-administracion-de-la-quimioterapia 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/microbiotic-product-to-promote-microbiome-health-and-improve-chemotherapy-delivery 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06792695/un-estudio-de-nuevas-intervenciones-y-combinaciones-terapeuticas-en-participantes-con-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06792695/a-study-of-novel-study-interventions-and-combinations-in-participants-with-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-para-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/lyl273-for-patients-with-relapsed-or-refractory-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/un-estudio-aleatorizado-doble-ciego-controlado-con-placebo-de-grupos-paralelos-comparativo-de-fase-iii-para-evaluar-la-eficacia-y-la-seguridad-de-las-capsulas-de-nuvastatic-r-de-300-mg-en-la 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/a-randomized-double-blind-placebo-controlled-parallel-group-comparative-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-nuvastatic-r-300mg-capsule-in-reducing-cancer-tumor-in-patients-with 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934538/ensayo-clinico-de-fase-i-de-stc-1010-una-inmunoterapia-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-irresecable 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934538/first-in-human-trial-of-stc-1010-an-immunotherapy-in-patients-with-unresectable-locally-advanced-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05838768/estudio-de-hro761-en-monoterapia-o-en-combinacion-en-pacientes-con-cancer-que-presenten-alteraciones-especificas-en-el-adn-denominadas-inestabilidad-de-microsatelites-o-deficiencia-en-la-reparacion 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05838768/study-of-hro761-alone-or-in-combination-in-cancer-patients-with-specific-dna-alterations-called-microsatellite-instability-or-mismatch-repair-deficiency 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03965234/perfusion-pulmonar-para-el-control-de-la-enfermedad-residual-minima-en-pacientes-con-sarcoma-o-metastasis-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07448662/estrategias-de-tratamiento-local-para-las-metastasis-cerebrales-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07448662/local-treatment-strategies-for-brain-metastases-of-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05248581/trasplante-hepatico-de-donante-vivo-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05248581/living-donor-liver-transplant-for-unresectable-colorectal-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-nuevas-terapias-oncologicas-en-combinacion-con-quimioterapia-y-bevacizumab-como-terapia-de-primera-linea-en-el-crc-mss 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-novel-oncology-therapies-in-combination-with-chemotherapy-and-bevacizumab-as-first-line-therapy-in-mss-crc 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/imagenes-moleculares-de-la-expresion-de-la-proteina-de-activacion-de-fibroblastos-mediante-el-uso-de-fapi-marcado-con-tecnecio-99m-hynic 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/molecular-imaging-of-fibroblast-activation-protein-expression-using-labeled-technetium-99m-hynic-fapi 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07595276/comparacion-de-la-eficacia-y-la-seguridad-de-enlituo-r-frente-a-erbitux-r-mas-folfox-en-el-cancer-colorrectal-localmente-avanzado-metastasico-con-estado-ras-braf-de-tipo-salvaje-y-mss-pmmr 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparing-efficacy-and-safety-of-enlituo-r-versus-erbitux-r-plus-folfox-in-locally-advanced-metastatic-colorectal-cancer-with-ras-braf-wild-type-and-mss-pmmr-status 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06896162/progreso-oncologia-de-precision-mediante-evaluaciones-genomicas-reflexivas-para-la-seleccion-de-estudios-y-la-supervivencia 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06896162/progress-precision-oncology-using-genomic-reflexive-evaluations-for-study-selection-and-survival 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06115733/estudio-de-fuquinitinib-en-combinacion-con-capecitabina-como-tratamiento-de-mantenimiento-de-primera-linea-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115733/study-of-fuquinitinib-combined-with-capecitabine-first-line-maintenance-in-the-treatment-of-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05727163/folfox-administrado-por-via-hai-mas-irinotecan-intravenoso-con-o-sin-bevacizumab-frente-a-folfoxiri-sistemico-con-o-sin-bevacizumab-en-pacientes-con-metastasis-hepaticas-colorrectales-crlm 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-via-hai-plus-intravenous-irinotecan-with-or-without-bevacizumab-versus-systemic-folfoxiri-with-or-without-bevacizumab-in-initially-unresectable-ras-mutated-crlm-patients 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07602504/base-de-datos-del-registro-clinico-chino-de-pacientes-con-cancer-de-higado-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07602504/china-metastatic-liver-cancer-clinical-registry-cohort-database 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682247/un-estudio-en-el-mundo-real-de-chidamide-en-combinacion-con-anticuerpos-anti-pd-1-pd-l1-y-agentes-antiangiogenicos-en-el-cancer-colorrectal-avanzado-mss 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682247/a-real-world-study-of-chidamide-in-combination-with-pd-1-pd-l1-antibodies-and-anti-angiogenic-agents-in-advanced-mss-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04258137/adn-circulante-para-mejorar-el-pronostico-de-los-pacientes-oncologicos-un-estudio-aleatorizado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04258137/circulating-dna-to-improve-outcome-of-oncology-patient-a-randomized-study 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-y-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-and-bevacizumab-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/bloqueo-dual-de-egfr-her2-combinado-con-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico-her2-positivo 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/dual-egfr-her2-blockade-combined-with-irinotecan-for-the-treatment-of-her2-positive-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06558773/inhibidor-de-la-sintetasa-gsl-en-combinacion-con-un-inhibidor-del-punto-de-control-inmunitario-y-o-regorafenib-en-pacientes-con-cancer-colorrectal-pmmr-mss-previamente-tratados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06558773/gsl-synthetase-inhibitor-plus-immune-checkpoint-inhibitor-and-or-regorafenib-in-previously-treated-pmmr-mss-crc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/un-estudio-de-abt-301-mas-tislelizumab-con-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-pmmr-no-msi-h 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/a-study-of-abt-301-plus-tislelizumab-with-bevacizumab-in-pmmr-non-msi-h-locally-advanced-or-mcrc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04622423/terapias-avanzadas-para-metastasis-hepaticas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04622423/advanced-therapies-for-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02688712/estudio-exist-de-ly2157299-galunisertib-en-cancer-de-recto 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02688712/exist-study-of-ly2157299-galunisertib-in-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02246634/deteccion-de-metastasis-sincronicas-en-el-cancer-colorrectal-mediante-resonancia-magnetica-con-difusion-serenade 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotina-en-combinacion-con-cetuximab-en-el-tratamiento-en-lineas-posteriores-del-cancer-colorrectal-metastasico-con-ras-tipo-salvaje 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotin-combined-with-cetuximab-in-the-later-line-treatment-of-metastatic-ras-wild-type-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04802876/eficacia-de-tislelizumab-y-spartalizumab-en-diversos-tipos-de-cancer-en-pacientes-con-tumores-que-expresan-altos-niveles-de-arnm-de-pd1 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04802876/efficacy-of-tislelizumab-and-spartalizumab-across-multiple-cancer-types-in-patients-with-pd1-high-mrna-expressing-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06265025/inyeccion-intratumoral-de-gm103-en-pacientes-con-tumores-solidos-avanzados-localmente-irresecables-refractarios-y-o-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06265025/gm103-intratumoral-injection-in-patients-with-locally-advanced-unresectable-refractory-and-or-metastatic-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-temozolomida-y-m1774-para-determinar-su-seguridad-y-eficacia 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/un-ensayo-de-expansion-de-dosis-de-hnf4-srrna-intravenoso-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/a-dose-expansion-trial-of-intravenous-hnf4-srrna-for-unresectable-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/estudio-de-inhibidores-de-ras-on-en-pacientes-con-tumores-solidos-gastrointestinales 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/study-of-ras-on-inhibitors-in-patients-with-gastrointestinal-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007689/un-estudio-multi-omico-del-cancer-colorrectal-con-mutacion-braf-v600e 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007689/a-multi-omics-study-of-braf-v600e-mutant-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07030257/estudio-de-cp-383-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/study-of-cp-383-in-patients-with-advanced-or-metastatic-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07306390/distribucion-y-analisis-de-los-ganglios-linfaticos-metastasicos-en-pacientes-con-cancer-colorrectal-diamond 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07306390/distribution-and-analysis-of-metastatic-lymph-nodes-in-colorectal-cancer-patients-diamond 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05059444/oracle-observacion-de-enfermedad-residual-mediante-evaluacion-con-biopsia-liquida 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05059444/oracle-observation-of-residual-cancer-with-liquid-biopsy-evaluation 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/un-estudio-de-fase-ii-de-sintilimab-en-combinacion-con-ipilimumab-n01-cetuximab-y-dabrafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-y-mutacion-braf-v600e 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/a-phase-ii-study-of-sintilimab-combined-with-ipilimumab-n01-cetuximab-and-dabrafenib-in-patients-with-microsatellite-stable-braf-v600e-mutated-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/un-enfoque-terapeutico-multimodal-personalizado-integrado-y-adaptado-al-estadio-a-nivel-mundial-para-el-adenocarcinoma-rectal-basado-en-la-preservacion-de-organos-y-la-minima-invasion 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/a-global-integrated-personalized-stage-related-multimodal-therapeutic-approach-for-rectal-adenocarcinoma-based-on-organ-sparing-and-mininvasivity 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02432963/terapia-con-vacunas-y-pembrolizumab-en-el-tratamiento-de-pacientes-con-tumores-solidos-que-no-han-respondido-a-terapias-previas 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02432963/vaccine-therapy-and-pembrolizumab-in-treating-patients-with-solid-tumors-that-have-failed-prior-therapy 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/un-estudio-de-fruquintinib-en-adultos-con-cancer-colorrectal-metastasico-en-polonia 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/a-study-of-fruquintinib-in-adults-with-metastatic-colorectal-cancer-in-poland 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07512674/radioterapia-de-curso-corto-modificada-combinada-con-inmunoterapia-quimioterapia-y-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-mss 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07512674/modified-short-course-radiotherapy-combined-with-immunochemotherapy-and-targeted-therapy-as-first-line-treatment-for-mss-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/inyeccion-de-ip-001-en-tumores-hepaticos-sometidos-a-ablacion-termica-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/injection-of-ip-001-into-thermally-ablated-hepatic-tumors-in-patients-with-colorectal-liver-metastases 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06839105/un-estudio-clinico-para-evaluar-la-seguridad-y-la-tolerabilidad-de-awt020-en-pacientes-con-tumores-malignos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06839105/a-clinical-study-to-evaluate-the-safety-and-tolerability-of-awt020-in-patients-with-advanced-malignancies 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342440/deteccion-temprana-de-adenomas-avanzados-y-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342440/early-detection-of-advanced-adenomas-and-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07334587/comparacion-de-la-eficacia-y-la-seguridad-entre-folfox-6-y-capox-en-el-carcinoma-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparison-of-efficacy-and-safety-between-folfox-6-and-capox-in-metastatic-colorectal-carcinoma 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636785/un-estudio-de-fase-1-y-2-de-vmd-102-en-carcinoma-hepatocelular-y-otros-tumores-solidos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636785/a-phase-1-and-2-study-of-vmd-102-in-hepatocellular-carcinoma-and-other-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06475352/individualizacion-de-la-dosis-de-quimioterapia-en-pacientes-con-canceres-gastrointestinales-que-carecen-de-una-enzima-hepatica-especifica 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/dose-individualization-of-chemotherapy-in-patients-with-gastrointestinal-cancers-lacking-a-specific-liver-enzyme 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-zen003694-al-tratamiento-de-quimioterapia-habitual-capecitabina-para-canceres-metastasicos-o-irresecables 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/testing-the-addition-of-an-anti-cancer-drug-zen003694-to-the-usual-chemotherapy-treatment-capecitabine-for-metastatic-or-unresectable-cancers 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201352/evaluacion-de-la-eficacia-de-trifluridina-tipiracil-mas-un-anticuerpo-humano-verdadero-anti-il-1-frente-a-trifluridina-tipiracil-mas-placebo-en-pacientes-con-cancer-colorrectal-metastasico-despues 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluation-of-efficacy-of-trifluridine-tipiracil-plus-an-anti-il-1-true-human-antibody-versus-trifluridine-tipiracil-plus-placebo-in-metastatic-colorectal-cancer-patients-after-failure-of-oxaliplatin 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06723236/un-estudio-de-mgc028-en-participantes-con-tumores-solidos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06723236/a-study-of-mgc028-in-participants-with-advanced-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridina-tipiracil-mas-panitumumab-frente-a-trifluridina-tipiracil-mas-bevacizumab-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridine-tipiracil-plus-panitumumab-versus-trifluridine-tipiracil-plus-bevacizumab-as-first-line-treatment-of-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07649655/emb-01-en-combinacion-con-quimioterapia-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07649655/emb-01-in-combination-with-chemotherapy-for-unresectable-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07535632/radioterapia-estereotactica-ablativa-sbrt-seguida-de-un-inhibidor-de-pd-1-bevacizumab-y-tas-102-como-terapia-de-tercera-linea-para-el-cancer-colorrectal-recurrente-o-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07535632/sbrt-followed-by-pd-1-inhibitor-bevacizumab-and-tas-102-as-third-line-therapy-for-recurrent-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07348211/primer-estudio-en-humanos-de-sim0610-en-tumores-solidos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07348211/first-in-human-study-of-sim0610-in-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-en-pacientes-con-tumores-solidos-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07544589/un-estudio-de-fase-i-que-evalua-disp-10-en-participantes-con-canceres-gastrointestinales-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07544589/a-phase-1-study-evaluating-disp-10-in-participants-with-advanced-gastrointestinal-cancers 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/quimioterapia-intraabdominal-en-aerosol-a-presion-con-mitomicina-para-el-tratamiento-del-cancer-de-apendice-o-de-colon-recto-irresecable-con-metastasis-peritoneales-el-ensayo-impact 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/pressurized-intraperitoneal-aerosolized-chemotherapy-with-mitomycin-for-the-treatment-of-unresectable-appendix-or-colorectal-cancer-with-peritoneal-metastases-the-impact-trial 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabina-y-atezolizumab-para-el-cancer-colorrectal-oligo-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361016/comparacion-de-la-reseccion-total-mesocolica-laparoscopica-y-abierta-con-ligadura-vascular-central-para-el-carcinoma-de-colon-derecho 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07361016/comparison-of-laparoscopic-and-open-total-mesocolic-excision-with-central-vascular-ligation-for-right-colon-carcinoma 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04999761/estudio-de-la-plataforma-ab122 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04999761/ab122-platform-study 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-y-adg126-solos-y-en-combinacion-con-leucovorina-y-fluorouracilo-o-el-regimen-folfiri-para-el-tratamiento-del-cancer-colorrectal-avanzado-metastasico-con-estabilidad-microsatelital 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-and-adg126-alone-and-in-combination-with-leucovorin-and-fluorouracil-or-folfiri-regimen-for-the-treatment-of-microsatellite-stable-advanced-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/terapia-con-celulas-nk-alogenicas-combinada-con-el-tratamiento-de-mantenimiento-estandar-en-tumores-solidos-avanzados 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/allogeneic-nk-cell-therapy-combined-with-standard-maintenance-treatment-in-advanced-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05686226/inmunoterapia-con-celulas-t-modificadas-con-e7-para-el-tratamiento-de-los-canceres-asociados-al-virus-del-papiloma-humano-vph 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05686226/e7-tcr-t-cell-immunotherapy-for-human-papillomavirus-hpv-associated-cancers 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03157128/un-estudio-de-selpercatinib-loxo-292-en-participantes-con-tumores-solidos-avanzados-tumores-solidos-con-fusion-de-ret-y-cancer-de-tiroides-medular-libretto-001 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03157128/a-study-of-selpercatinib-loxo-292-in-participants-with-advanced-solid-tumors-ret-fusion-positive-solid-tumors-and-medullary-thyroid-cancer-libretto-001 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05176483/estudio-de-zanzalitinib-en-combinacion-con-agentes-de-inmunooncologia-en-participantes-con-tumores-solidos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05176483/study-of-zanzalintinib-in-combination-with-immuno-oncology-agents-in-participants-with-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/cancer-colorrectal-en-estadio-ii-iii-con-recurrencia 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/stage-ii-iii-colorectal-cancer-recurrence 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04281667/preparacion-mecanica-del-intestino-y-antibioticos-orales-frente-a-la-preparacion-mecanica-del-intestino-unicamente-en-pacientes-sometidos-a-cirugia-rectal-previa 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04281667/mechanical-bowel-preparation-and-oral-antibiotics-versus-mechanical-bowel-preparation-only-prior-rectal-surgery 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06126406/estudio-clinico-de-linfocitos-t-con-receptores-quimericos-de-antigenos-car-t-dirigidos-contra-el-cea-para-tumores-solidos-malignos-avanzados-con-expresion-de-cea 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126406/clinical-study-of-cea-targeting-chimeric-antigen-receptor-t-lymphocytes-car-t-for-cea-positive-advanced-malignant-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04981119/analisis-de-tumores-solidos-para-detectar-la-perdida-de-heterocigosidad-loh-de-hla-y-aferesis-para-la-fabricacion-de-celulas-car-t 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04981119/solid-tumor-analysis-for-hla-loss-of-heterozygosity-loh-and-apheresis-for-car-t-cell-manufacturing 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/pet-ct-con-f-triptofano-en-canceres-humanos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/f-tryptophan-pet-ct-in-human-cancers 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/quimioterapia-oral-terapia-dirigida-e-inmunoterapia-con-o-sin-radioterapia-como-terapia-de-tercera-linea-o-posterior-para-el-cancer-colorrectal-avanzado-mss-pmmr 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/oral-chemotherapy-targeted-therapy-and-immunotherapy-with-without-radiotherapy-as-3rd-or-later-line-therapy-for-advanced-mss-pmmr-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224815/biomarcadores-de-cfdna-5mc-5hmc-para-predecir-la-respuesta-a-la-quimioterapia-en-el-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224815/cfdna-5mc-5hmc-biomarkers-to-predict-chemotherapy-response-in-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05217446/un-estudio-de-encorafenib-mas-cetuximab-administrados-en-combinacion-con-pembrolizumab-en-comparacion-con-pembrolizumab-solo-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05217446/a-study-of-encorafenib-plus-cetuximab-taken-together-with-pembrolizumab-compared-to-pembrolizumab-alone-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06266832/eficacia-y-seguridad-de-la-radioterapia-de-corta-duracion-combinada-con-adebrelimab-y-la-terapia-neoadyuvante-capeox-para-la-preservacion-de-organos-en-pacientes-con-adenocarcinoma-rectal-ultra-bajo 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06266832/the-efficacy-and-safety-of-short-course-radiation-combined-with-adebrelimab-and-capeox-neo-adjuvant-therapy-for-organ-retention-in-patients-with-mss-pmmr-ultra-low-rectal-adenocarcinoma 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/creacion-de-un-biobanco-de-tumores-a-partir-de-muestras-de-sangre 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/establishment-of-a-tumor-bank-for-blood-samples 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06553885/estudio-de-fase-ii-de-enfortumab-vedotina-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico-o-carcinoma-hepatocelular 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06553885/ph-ii-study-of-enfortumab-vedotin-in-patients-with-advanced-or-metastatic-crc-or-hcc 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03350126/relevancia-de-la-evaluacion-irecist-para-la-tasa-de-respuesta-global-dcr-en-pacientes-con-cancer-colorrectal-metastasico-mmr-msi-tratados-con-nivolumab-e-ipilimumab 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/irecist-evaluation-s-relevance-for-dcr-in-mmr-msi-metastatic-colorectal-cancer-patients-on-nivolumab-and-ipilimumab 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06130280/un-estudio-sobre-la-radioterapia-estereotactica-de-cuerpo-unico-sbrt-guiada-por-resonancia-magnetica-rm-en-pacientes-con-metastasis-hepaticas-procedentes-del-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130280/a-study-of-single-fraction-stereotactic-body-radiation-therapy-sbrt-guided-by-magnetic-resonance-imaging-mri-in-people-with-liver-metastasis-from-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05308446/evaluacion-de-la-adicion-de-nivolumab-al-tratamiento-estandar-para-pacientes-con-cancer-colorrectal-metastasico-o-irresecable-que-presentan-una-mutacion-en-el-gen-braf 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05308446/testing-the-addition-of-nivolumab-to-standard-treatment-for-patients-with-metastatic-or-unresectable-colorectal-cancer-that-have-a-braf-mutation 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07417488/vacunacion-con-gucy2c-mediante-estrategia-prime-boost-para-adenocarcinoma-colorrectal-avanzado-y-adenocarcinoma-de-intestino-delgado 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07417488/gucy2c-prime-boost-vaccination-for-advanced-colorectal-and-small-bowel-adenocarcinomas 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06983743/un-estudio-de-eras-0015-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06983743/a-study-of-eras-0015-in-patients-with-advanced-or-metastatic-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03050268/investigacion-de-casos-familiares-de-predisposicion-al-cancer-infantil 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03050268/familial-investigations-of-childhood-cancer-predisposition 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341296/estudio-de-fase-ii-de-liposomas-de-irinotecan-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341296/phase-ii-study-of-irinotecan-liposomes-in-first-line-treatment-of-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959589/eficacia-y-seguridad-de-ibi351-cetuximab-en-combinacion-con-folfiri-como-tratamiento-de-primera-linea-y-de-ibi351-cetuximab-como-tratamiento-de-segunda-linea-en-el-tratamiento-del-cancer-colorrectal 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959589/the-efficacy-and-safety-of-ibi351-cetuximab-combined-with-folfiri-as-first-line-ibi351-cetuximab-as-second-line-in-the-treatment-of-kras-g12c-mutated-metastatic-colorectal-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/un-estudio-de-seguridad-tolerabilidad-y-eficacia-de-nc410-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos-avanzados-irresecables-o-metastasicos 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/a-safety-tolerability-and-efficacy-study-of-nc410-plus-pembrolizumab-in-participants-with-advanced-unresectable-or-metastatic-solid-tumors 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/trasplante-hepatico-y-cancer-colorrectal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/liver-transplantation-and-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07219238/estudio-para-evaluar-el-rendimiento-diagnostico-de-la-inyeccion-de-geh300079-68ga-para-pet-tc-en-la-deteccion-de-metastasis-de-cancer-de-pancreas-en-pacientes-con-cancer-colorrectal-gastrico-ovarico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07219238/study-to-evaluate-the-diagnostic-performance-of-geh300079-68ga-injection-pet-ct-for-detection-of-pc-in-patients-with-colorectal-gastric-ovarian-or-pancreatic-cancers-periscope 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07223047/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-de-bms-986523-tanto-en-monoterapia-como-en-combinacion-con-agentes-antineoplasicos-en-participantes-con-tumores-solidos-avanzados 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07223047/a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-bms-986523-alone-and-in-combination-with-anti-cancer-agents-in-participants-with-advanced-solid-malignancies 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07191548/estudio-internacional-sobre-el-tratamiento-de-pacientes-con-lesiones-hepaticas-metastasicas-de-cancer-colorrectal-pacientes-con-ire 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07191548/international-study-on-treatment-of-patients-with-metastatic-colorectal-liver-lesions-patients-with-ire 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224750/una-firma-de-microarn-no-invasiva-para-el-cribado-del-cancer-gastrointestinal 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224750/a-noninvasive-and-screening-mirna-signature-for-gastrointestinal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03908788/deteccion-de-la-aparicion-de-mutaciones-en-el-gen-ras-homologo-del-oncogen-viral-del-sarcoma-de-rata-en-el-adn-circulante-acido-desoxirribonucleico-en-pacientes-con-ccrc-metastasico-cancer 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03908788/detection-of-the-emergence-of-ras-rat-sarcoma-viral-oncogene-homolog-mutations-in-circulating-dna-deoxyribonucleic-acid-in-patients-with-mcrc-metastatic-colorectal-cancer-during-treatment-with-anti 2026-07-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07462143/un-ensayo-clinico-de-fase-ii-iii-con-rc148-mas-quimioterapia-como-terapia-de-primera-linea-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/a-phase-ii-iii-clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-06-24 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-06-24 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/venetoclax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/venetoclax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gm-ct-01 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/gm-ct-01/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2497/el-anticuerpo-anti-tigit-30-278-igg1-rmd-con-una-fraccion-cristalizable-fc-mejorada-amplifica-la-inmunidad-antitumoral-mediante-la-activacion-de-las-celulas-efectoras-y-presenta-una-accion-sinergica 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2497/fc-enhanced-anti-tigit-antibody-30-278-igg1-rmd-amplifies-antitumor-immunity-through-effector-cell-activation-and-synergizes-with-pd-1-blockade 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2495/descifrando-los-mecanismos-funcionales-de-eif3f-en-los-tumores-y-explorando-terapias-dirigidas 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2495/deciphering-the-functional-mechanisms-of-eif3f-in-tumors-and-exploring-targeted-therapies 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2420/la-cefarantina-induce-la-muerte-celular-inmunogenica-en-tumores-solidos-al-suprimir-la-expresion-de-la-poli-adp-ribosa-polimerasa-1-mediada-por-la-proteina-quinasa-c-zeta-y-presenta-una-accion 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2420/cepharanthine-triggers-immunogenic-cell-death-in-solid-tumors-by-suppressing-protein-kinase-c-zeta-mediated-poly-adp-ribose-polymerase-1-expression-and-synergizes-with-immunotherapy 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2405/eficacia-y-seguridad-comparativas-de-los-tratamientos-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-una-revision-sistematica-y-un-metaanalisis-de-red 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2405/comparative-efficacy-and-safety-of-first-line-treatments-for-ras-wild-type-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2393/diferencias-raciales-y-etnicas-en-los-resultados-del-cribado-del-cancer-de-prostata-en-los-estados-unidos-un-analisis-secundario-del-ensayo-sobre-el-cancer-de-prostata-pulmon-colon-y-ovario 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2393/racial-and-ethnic-differences-in-prostate-cancer-screening-outcomes-in-the-united-states-a-secondary-analysis-of-the-prostate-lung-colorectal-and-ovarian-cancer-trial 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-la-integracion-de-aprendizaje-profundo-y-metodos-estadisticos-revela-patrones-espaciales-del-estroma-y-del-sistema-inmunitario-en-el-cancer-colorrectal-agresivo 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-deep-learning-statistical-integration-reveals-spatial-stromal-and-immune-signatures-of-aggressive-colon-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2250/caracterizacion-espectroscopica-raman-de-los-cambios-proteicos-inducidos-por-el-5-fluorouracilo-en-celulas-de-cancer-de-colon 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2250/raman-spectroscopic-characterization-of-protein-changes-induced-by-5-fluorouracil-in-colon-cancer-cells 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-en-combinacion-con-3-metiladenina-para-el-tratamiento-del-cancer-de-pancreas-con-mutacion-kras-g12c-y-sus-mecanismos-subyacentes 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-combined-with-3-methyladenine-for-the-treatment-of-kras-g12c-mutant-pancreatic-cancer-and-its-underlying-mechanisms 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2212/metastasis-hepaticas-de-cancer-colorrectal-estrategias-de-imagen-para-el-diagnostico-la-planificacion-del-tratamiento-local-y-la-evaluacion-de-la-respuesta-al-tratamiento-sistemico 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2212/colorectal-liver-metastases-imaging-strategies-for-diagnosis-local-treatment-planning-and-systemic-treatment-response 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2155/eficacia-de-la-dieta-mediterranea-para-la-prevencion-primaria-de-enfermedades-oncologicas-una-revision-sistematica-y-metaanalisis-que-se-incluye-en-las-guias-nacionales-italianas-la-dieta-mediterranea 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2155/efficacy-of-mediterranean-diet-for-the-primary-prevention-of-oncological-diseases-a-systematic-review-and-meta-analysis-featured-in-the-italian-national-guidelines-la-dieta-mediterranea 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2096/descifrando-la-heterogeneidad-de-las-celulas-del-cancer-colorrectal-identificacion-de-biomarcadores-y-subpoblaciones-celulares-impulsoras-de-la-enfermedad-mediante-scissor-y-cibersortx-en-el-analisis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2096/unveiling-colorectal-cancer-cell-heterogeneity-identification-of-biomarkers-and-disease-driving-cell-subpopulations-through-scissor-and-cibersortx-on-integrated-transcriptomic-profiling 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2095/el-aprendizaje-profundo-consciente-de-firmas-revela-distintos-programas-de-genes-conductores-y-procesos-mutacionales-en-glioblastoma-y-adenocarcinoma-de-colon 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2095/signature-aware-deep-learning-reveals-distinct-driver-gene-programs-and-mutational-processes-in-glioblastoma-and-colon-adenocarcinoma 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/1498/una-plataforma-nano-basada-en-manganeso-que-aprovecha-los-efectos-quimiodynammaticos-y-adjutivos-para-la-vacunacion-in-situ-contra-el-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/1498/a-manganese-based-nanoplatform-leveraging-chemodynamic-and-adjuvant-effects-for-in-situ-vaccination-against-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2623/conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-panorama-actual-y-perspectivas-futuras-a-partir-de-los-ensayos-clinicos 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2623/antibody-drug-conjugates-in-colorectal-cancer-current-landscape-and-future-perspectives-from-clinical-trials 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2621/un-estudio-retrospectivo-de-los-factores-pronosticos-diferenciales-en-el-cancer-colorrectal-de-inicio-temprano-frente-al-de-inicio-tardio-un-analisis-clinico-exhaustivo-y-basado-en-el-aprendizaje 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2621/a-retrospective-study-of-differential-prognostic-factors-in-early-onset-versus-late-onset-colorectal-cancer-a-comprehensive-clinical-and-machine-learning-analysis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2620/la-dihidroartemisinina-inhibe-la-forma-mutada-de-kras-para-potenciar-el-efecto-de-regorafenib-y-un-anticuerpo-anti-pd-1-en-metastasis-hepaticas-de-cancer-colorrectal-con-mutacion-en-el-gen-kras 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2620/dihydroartemisinin-inhibits-mutant-kras-to-potentiate-regorafenib-plus-anti-pd-1-in-kras-mutant-colorectal-cancer-liver-metastases 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2619/mayor-frecuencia-de-mutaciones-subclonales-de-resistencia-a-egfr-en-las-muestras-obtenidas-tras-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-recibir 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2619/higher-frequency-of-subclonal-anti-egfr-resistance-mutations-in-post-treatment-samples-from-patients-with-colorectal-cancer-liver-metastases-following-anti-egfr-based-conversion-chemotherapy 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2512/el-pai-1-derivado-de-las-celulas-asociadas-al-cancer-actua-como-ligando-de-egfr-y-promueve-el-crecimiento-del-cancer-de-pancreas-con-mutaciones-en-kras 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2512/caf-derived-pai-1-serves-as-an-egfr-ligand-and-fuels-kras-mutant-pancreatic-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2508/la-volumetria-tumoral-y-de-organos-basada-en-inteligencia-artificial-predice-la-progresion-temprana-tras-la-radioembolizacion-con-y-90-en-la-enfermedad-metastasica-con-predominio-hepatico 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2508/ai-based-tumor-and-organ-volumetry-predicts-early-progression-after-y-90-radioembolization-in-liver-dominant-metastatic-disease 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2504/quien-rechaza-el-asesoramiento-genetico-evaluacion-del-rechazo-al-asesoramiento-genetico-entre-los-participantes-en-un-programa-de-cribado-genomico-a-nivel-poblacional 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2504/who-declines-genetic-counseling-an-assessment-of-genetic-counseling-declination-among-individuals-participating-in-a-population-wide-genomic-screening-program 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2503/resultados-de-los-inhibidores-del-receptor-del-factor-de-crecimiento-epidermico-en-el-carcinoma-de-celulas-escamosas-anal-localmente-avanzado-y-metastasico-una-revision-sistematica-y-metaanalisis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2503/outcomes-of-epidermal-growth-factor-receptor-inhibitors-in-locally-advanced-and-metastatic-anal-squamous-cell-carcinoma-a-systematic-review-and-meta-analysis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2496/prediccion-de-las-nauseas-inducidas-por-la-quimioterapia-durante-el-tratamiento-con-irinotecan-basandose-en-los-sintomas-previos-inducidos-por-el-oxaliplatino-en-el-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2496/prediction-of-chemotherapy-induced-nausea-during-irinotecan-based-treatment-based-on-prior-oxaliplatin-induced-symptoms-in-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2494/la-senalizacion-mediada-por-vesiculas-extracelulares-en-el-cancer-impulsada-por-la-obesidad-aspectos-mecanisticos-e-implicaciones-clinicas 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2494/obesity-driven-extracellular-vesicle-signaling-in-cancer-mechanistic-insights-and-clinical-implications 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2493/las-celulas-t-nmb-cxcl13-cd4-producen-neuromedina-b-lo-que-promueve-la-senescencia-y-la-malignidad-de-las-celulas-malignas-positivas-para-el-receptor-1-de-la-neuropeptida-s 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2493/nmb-cxcl13-cd4-t-cell-derived-neuromedin-b-promotes-neuropeptide-s-receptor-1-positive-malignant-cell-senescence-and-malignancy 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2492/aplicacion-de-los-resultados-del-estudio-cleopatra-en-la-practica-clinica-habitual-patrones-de-tratamiento-nacionales-y-supervivencia-en-pacientes-con-cancer-de-mama-metastasico-her2-positivo 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2492/translating-cleopatra-into-routine-practice-national-treatment-patterns-and-survival-for-patients-with-her2-positive-metastatic-breast-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2490/la-decoccion-de-sini-inhibe-la-metastasis-hepatica-del-cancer-colorrectal-al-suprimir-la-senalizacion-de-integrinas-exosomicas-dependiente-de-hif-1 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2490/sini-decoction-inhibits-colorectal-cancer-liver-metastasis-by-suppressing-hif-1-dependent-exosomal-integrin-signaling 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2488/la-decoccion-xianlian-jiedu-induce-la-apoptosis-en-el-cancer-colorrectal-mediante-la-modulacion-de-la-senalizacion-jnk-p38-mapk-dependiente-de-la-esfingosina-1-fosfato 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2488/xianlian-jiedu-decoction-induces-apoptosis-in-colorectal-cancer-via-modulation-of-sphingosine-1-phosphate-dependent-jnk-p38-mapk-signaling 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2487/el-analisis-multi-omico-de-la-suplementacion-con-saccharomyces-boulardii-revela-cambios-coordinados-en-el-microbioma-el-metabolismo-y-la-senalizacion-inmune-que-acompanan-a-la-supresion-tumoral 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2487/multi-omics-analysis-of-saccharomyces-boulardii-supplementation-reveals-coordinated-microbiome-metabolic-and-immune-signaling-changes-accompanying-tumor-suppression 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2486/nt5e-favorece-la-progresion-del-cancer-colorrectal-y-se-correlaciona-con-la-expresion-de-pd-l1-evidencia-obtenida-a-partir-de-analisis-multiomicos-muestras-clinicas-y-ensayos-funcionales-celulares 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2486/nt5e-promotes-colorectal-cancer-progression-and-correlates-with-pd-l1-expression-evidence-from-multi-omics-analysis-clinical-samples-and-cellular-functional-assays 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2485/diseno-y-sintesis-de-un-inhibidor-de-fak-altamente-eficaz-para-el-tratamiento-potencial-del-cancer-colorrectal-que-presenta-la-mutacion-kras 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2485/the-design-and-synthesis-of-highly-efficient-fak-inhibitor-for-the-potential-treatment-of-colorectal-cancer-harboring-kras-mutation 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2484/impacto-clinico-del-estado-de-mutacion-del-homologo-del-oncogen-viral-del-sarcoma-de-la-rata-de-kirsten-kras-en-los-patrones-de-recidiva-y-en-la-eficacia-del-tratamiento-local-tras-una-hepatectomia 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2484/clinical-impact-of-kirsten-rat-sarcoma-viral-oncogene-homolog-kras-mutation-status-on-recurrence-patterns-and-the-efficacy-of-local-therapy-after-hepatectomy-for-colorectal-liver-metastases 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2483/identificacion-sistematica-de-biomarcadores-genomicos-de-falta-de-respuesta-a-los-tratamientos-contra-el-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2483/systematic-identification-of-genomic-nonresponse-biomarkers-to-cancer-therapies 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2481/un-adenovirus-oncolitico-modificado-con-un-inhibidor-de-cdk4-6-revierte-el-agotamiento-de-las-celulas-t-a-traves-de-la-via-rb-p65-ccl5-y-potencia-la-actividad-antitumoral-de-la-terapia-anti-pd-1-o 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2481/a-cdk4-6-inhibitor-armed-oncolytic-adenovirus-reverses-t-cell-exhaustion-through-the-rb-p65-ccl5-pathway-and-potentiates-the-antitumor-activity-of-anti-pd-1-or-car-t-therapy-in-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2480/un-adenovirus-oncolitico-modificado-con-icosl-activa-las-celulas-t-cd4-para-potenciar-la-inmunidad-antitumoral-y-presenta-una-accion-sinergica-con-la-terapia-anti-pd-1-o-la-terapia-con-celulas-car-t 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2480/an-icosl-armed-oncolytic-adenovirus-activates-cd4-t-cell-to-potentiate-antitumor-immunity-and-synergizes-with-anti-pd-1-or-car-t-cell-therapy-in-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2479/mecanismos-y-avances-en-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-una-revision-sistematica-de-las-redes-reguladoras-multicapa 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2479/mechanisms-and-advances-of-drug-resistance-in-colorectal-cancer-a-systematic-overview-of-multi-layered-regulatory-networks 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2477/cartografia-del-panorama-anatomico-de-los-tumores-colorrectales-eficacia-especifica-segun-la-localizacion-de-los-anticuerpos-contra-el-receptor-del-factor-de-crecimiento-epidermico-analisis-combinado 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2477/mapping-the-anatomical-landscape-of-colorectal-tumours-location-specific-efficacy-of-anti-epidermal-growth-factor-receptor-antibodies-pooled-analysis-of-randomised-trials 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2474/es-fusobacterium-nucleatum-el-principal-mediador-entre-las-infecciones-orales-y-las-enfermedades-sistemicas-perspectivas-mecanisticas-e-implicaciones-terapeuticas 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2474/is-fusobacterium-nucleatum-the-key-mediator-between-oral-infections-and-systemic-diseases-mechanistic-insights-and-therapeutic-implications 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2473/los-algoritmos-de-aprendizaje-automatico-desarrollan-una-firma-genica-relacionada-con-las-plaquetas-educadas-por-el-tumor-para-predecir-el-pronostico-del-cancer-colorrectal-y-la-respuesta-al 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2473/machine-learning-algorithms-develop-a-tumor-educated-platelets-related-gene-signature-to-predict-colorectal-cancer-prognosis-and-therapy-response 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2472/un-estudio-de-fase-ii-sobre-alpelisib-y-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado-kcsg-co21-04 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2472/a-phase-ii-study-of-alpelisib-and-capecitabine-in-patients-with-previously-treated-metastatic-colorectal-cancer-kcsg-co21-04 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2471/perfil-genomico-y-clinico-integrador-de-las-metastasis-hepaticas-del-cancer-colorrectal-para-orientar-la-cirugia-personalizada-y-el-trasplante-de-higado 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2471/integrative-genomic-and-clinical-profiling-of-colorectal-cancer-liver-metastases-to-guide-personalized-surgery-and-liver-transplantation 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2468/arquetipos-inmunitarios-espaciales-en-el-cancer-gastrico-y-colorrectal-un-marco-conceptual-propuesto-para-la-resistencia-a-la-inmunoterapia-y-la-remodelacion-terapeutica 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2468/spatial-immune-archetypes-in-gastric-and-colorectal-cancer-a-proposed-conceptual-framework-for-immunotherapy-resistance-and-therapeutic-remodeling 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2467/las-firmas-proteomicas-tisulares-del-cancer-colorrectal-con-mutacion-en-el-gen-braf-revelan-nuevos-conocimientos-sobre-la-agresividad-la-modulacion-inmune-y-la-reprogramacion-metabolica 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2467/tissue-proteomic-signatures-of-braf-mutated-colorectal-cancer-reveal-new-insights-into-aggressiveness-immune-modulation-and-metabolic-reprogramming 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2462/protocolo-del-estudio-administracion-dirigida-de-interleucina-12-en-combinacion-con-terapia-de-infusion-mediante-bomba-en-la-arteria-hepatica-para-pacientes-con-metastasis-hepaticas-de-carcinoma 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2462/study-protocol-targeted-delivery-of-interleukin-12-in-combination-with-hepatic-artery-infusion-pump-therapy-for-patients-with-adrenocortical-carcinoma-liver-metastases 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2461/objetivos-de-la-terapia-car-t-la-inteligencia-artificial-toma-el-control 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2461/car-t-targets-ai-takes-the-wheel 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2460/un-nuevo-paradigma-de-los-anticuerpos-biespecificos-en-el-manejo-clinico-de-los-canceres-gastrointestinales 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2460/a-new-paradigm-of-bispecific-antibodies-in-clinical-management-of-gastrointestinal-cancers 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2459/resultados-clinicos-del-regimen-folfiri-de-segunda-linea-mas-ramucirumab-segun-la-exposicion-previa-a-terapias-biologicas-en-el-cancer-colorrectal-metastasico-una-comparacion-retrospectiva-de-los 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2459/clinical-outcomes-of-second-line-folfiri-plus-ramucirumab-according-to-prior-biologic-exposure-in-metastatic-colorectal-cancer-a-retrospective-comparison-of-prior-bevacizumab-and-prior-anti-egfr 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2457/descubrimiento-mediante-inteligencia-artificial-de-celulas-car-t-dirigidas-a-gpnmb-como-terapia-para-multiples-tipos-de-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2457/ai-driven-discovery-of-gpnmb-car-t-cells-as-a-multi-cancer-therapy 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2456/conjugados-anticuerpo-farmaco-en-la-oncologia-de-tumores-solidos-y-la-frontera-de-la-inmunosupresion-de-precision-una-revision-mecanicista-traslacional-y-clinica 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2456/antibody-drug-conjugates-in-solid-tumor-oncology-and-the-frontier-of-precision-immunosuppression-a-mechanistic-translational-and-clinical-review 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2454/el-efecto-de-los-farmacos-antiinflamatorios-en-la-incidencia-del-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2454/the-effect-of-anti-inflammatory-drugs-on-the-incidence-of-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2453/inhibicion-sinergica-del-crecimiento-del-cancer-colorrectal-mediante-el-bloqueo-combinado-de-pi3k-y-cox-2-en-lineas-celulares-y-organoides-derivados-de-pacientes 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2453/synergistic-inhibition-of-colorectal-cancer-growth-by-combined-pi3k-and-cox-2-blockade-in-cell-lines-and-patient-derived-organoids 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2452/el-fenotipo-de-microsatelites-como-guia-para-la-inmunoterapia-en-el-cancer-colorrectal-estado-actual-y-perspectivas-futuras 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2452/microsatellite-phenotype-as-a-guide-for-immunotherapy-in-colorectal-cancer-current-status-and-future-perspectives 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2451/enfoque-indiferenciado-segun-el-tipo-de-tumor-en-tumores-solidos-un-metaanalisis-conforme-a-las-directrices-prisma-sobre-la-eficacia-la-seguridad-y-los-factores-determinantes-de-la-resistencia-en 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2451/tissue-agnostic-targeting-in-solid-tumors-a-prisma-compliant-meta-analysis-of-efficacy-safety-and-resistance-determinants-across-histologies 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2450/diferente-agresividad-molecular-y-clinica-en-el-cancer-colorrectal-metastasico-de-aparicion-muy-temprana-supervivencia-y-divergencia-genomica-entre-pacientes-de-30-a-39-anos-frente-a-pacientes-de-40 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2450/distinct-molecular-and-clinical-aggressiveness-in-very-early-onset-metastatic-colorectal-cancer-survival-and-genomic-divergence-between-patients-aged-30-39-versus-40-49-years 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2449/toxicidad-y-finalizacion-del-tratamiento-con-folfoxiri-neoadyuvante-y-quimiorradioterapia-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-un-analisis-secundario-de-los 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2449/toxicity-and-treatment-completion-of-neoadjuvant-folfoxiri-and-chemoradiotherapy-in-patients-with-high-risk-locally-advanced-rectal-cancer-a-secondary-outcome-analysis-of-the-mend-it-trial 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2447/empire-nsabp-fc-13-un-ensayo-de-fase-ii-basado-en-biomarcadores-que-evalua-una-terapia-inmunologica-basada-en-cemiplimab-en-cancer-colorrectal-con-estabilidad-microsatelital-y-enfermedad-residual 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2447/empire-nsabp-fc-13-a-biomarker-driven-phase-ii-platform-trial-evaluating-cemiplimab-based-immunotherapy-in-microsatellite-stable-colorectal-cancer-with-ctdna-defined-minimal-residual-disease 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2446/una-nueva-firma-genetica-relacionada-con-la-lactilacion-permite-comprender-el-microambiente-inmunosupresor-y-estratificar-la-terapia-de-precision-en-el-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2446/a-novel-lactylation-related-gene-signature-deciphers-the-immunosuppressive-microenvironment-and-stratifies-precision-therapy-in-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2445/avances-en-las-estrategias-de-conversion-basadas-en-la-terapia-sistemica-para-el-cancer-colorrectal-localmente-avanzado 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2445/advances-in-systemic-therapy-driven-conversion-strategies-for-locally-advanced-rectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2444/avances-en-la-evaluacion-del-estado-de-respuesta-tumoral-tras-la-terapia-neoadyuvante-para-el-cancer-de-recto 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2444/progress-in-the-evaluation-of-tumor-response-status-after-neoadjuvant-therapy-for-rectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2443/analisis-de-los-factores-de-riesgo-para-complicaciones-anastomoticas-graves-a-largo-plazo-tras-la-cirugia-de-cancer-de-recto 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2443/analysis-of-risk-factors-for-long-term-severe-anastomotic-complications-following-rectal-cancer-surgery 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2442/la-autofagia-mediada-por-tmem184a-en-la-degradacion-de-mhc-i-favorece-la-evasion-inmunitaria-tumoral 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2442/tmem184a-mediated-autophagy-in-mhc-i-degradation-promotes-tumor-immune-evasion 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2440/analisis-de-coste-efectividad-de-las-pruebas-de-adn-fecal-multiobjetivo-para-la-deteccion-del-cancer-colorrectal-en-centros-de-atencion-primaria-chinos-un-estudio-de-modelizacion 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2440/cost-effectiveness-of-multitarget-stool-dna-testing-for-colorectal-cancer-screening-in-chinese-primary-healthcare-settings-a-modelling-study 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2439/reutilizacion-in-silico-de-farmacos-aprobados-para-uso-clinico-como-posibles-inhibidores-de-braf-un-cribado-virtual-basado-en-farmacoforos-e-investigacion-experimental 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2439/in-silico-repurposing-of-clinically-approved-drugs-as-potential-braf-inhibitors-a-pharmacophore-based-virtual-screening-and-experimental-investigation 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2428/estratificacion-diagnostica-de-globo-h-e-identificacion-de-dusp14-como-un-posible-blanco-terapeutico-en-el-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2428/globo-h-diagnostic-stratification-and-identification-of-dusp14-as-a-candidate-target-in-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2426/evaluacion-de-pegenzileukin-sar444245-thor-707-en-combinacion-con-pembrolizumab-o-cetuximab-en-cancer-gastrointestinal-metastasico-avanzado-el-estudio-pegathor-de-fase-ii 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2426/evaluating-pegenzileukin-sar444245-thor-707-in-combination-with-pembrolizumab-or-cetuximab-in-advanced-metastatic-gastrointestinal-cancer-the-pegathor-phase-2-study 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2425/el-eje-adar1-circrab5a-bip-regula-la-resistencia-a-la-radioterapia-en-el-cancer-colorrectal-mediante-la-coordinacion-de-la-autofagia-protectora-y-la-apoptosis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2425/adar1-circrab5a-bip-axis-governs-radiotherapy-resistance-in-colorectal-cancer-through-coordinating-protective-autophagy-and-apoptosis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2424/mecanismos-y-estrategias-emergentes-para-superar-la-resistencia-a-la-inmunoterapia-en-tumores-frios-del-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2424/mechanisms-and-emerging-strategies-to-overcome-immunotherapy-resistance-in-cold-tumours-of-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2419/evaluacion-de-la-carga-de-los-canceres-asociados-al-vph-en-brasil-tendencias-de-hospitalizacion-y-mortalidad-de-2011-a-2019 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2419/assessing-the-burden-of-hpv-associated-cancers-in-brazil-hospitalization-and-mortality-trends-from-2011-to-2019 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2418/analisis-conjunto-de-2-ensayos-clinicos-sobre-quimioinmunoterapia-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-microsatelites-estables-estudios-meditreme-y-metimmox 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2418/pooled-analysis-of-2-clinical-trials-of-first-line-chemoimmunotherapy-for-metastatic-microsatellite-stable-colorectal-cancer-meditreme-and-metimmox-studies 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-para-el-carcinoma-colorrectal-analisis-de-la-evidencia-clinica-para-la-innovacion-en-el-diseno-molecular 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-for-colorectal-carcinoma-decoding-clinical-evidence-for-molecular-design-innovation 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2413/mir-31-como-biomarcador-predictivo-de-la-eficacia-del-cetuximab-en-pacientes-con-cancer-colorrectal-metastasico-revision-sistematica 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2413/mir-31-as-a-predictive-biomarker-of-cetuximab-efficacy-in-metastatic-colorectal-cancer-patients-systematic-review 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2411/una-revision-sistematica-exhaustiva-de-la-patogenia-molecular-de-los-canceres-del-sistema-digestivo-2013-2025 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2411/a-systematic-scoping-review-of-the-molecular-pathogenesis-of-digestive-system-cancers-2013-2025 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2409/avances-en-el-trasplante-hepatico-para-tumores-hepaticos-malignos 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2409/advances-in-liver-transplantation-for-hepatic-malignancies 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2408/los-fibroblastos-asociados-al-cancer-postn-forman-una-barrera-similar-a-una-fortaleza-que-contribuye-a-la-resistencia-a-la-inmunoterapia-en-el-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2408/postn-cancer-associated-fibroblasts-forming-fortress-like-barrier-to-mediate-immunotherapy-resistance-in-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2407/un-nuevo-conjugado-anticuerpo-farmaco-disenado-para-dirigirse-a-b7-h3-demuestra-una-mayor-eficacia-terapeutica-en-una-amplia-gama-de-canceres 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2407/a-newly-designed-antibody-drug-conjugate-targeting-b7-h3-demonstrates-enhanced-therapeutic-efficacy-across-a-spectrum-of-cancers 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2406/respuesta-completa-sostenida-al-tratamiento-con-la-plataforma-tmep-ci-m-en-un-cancer-de-pulmon-de-celulas-pequenas-refractario-con-metastasis-en-el-tronco-encefalico-informe-de-un-caso-con-mas-de-20 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2406/sustained-complete-response-to-tmep-ci-m-platform-in-refractory-small-cell-lung-cancer-with-brainstem-metastasis-a-case-report-with-over-20-months-of-disease-free-survival 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2403/resistencia-a-la-inmunoterapia-en-el-cancer-colorrectal-estrategias-terapeuticas-y-enfoques-guiados-por-biomarcadores 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2403/immunotherapy-resistance-in-colorectal-cancer-therapeutic-strategies-and-biomarker-guided-approaches 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2401/factores-de-riesgo-tipos-de-cancer-y-significado-pronostico-del-segundo-cancer-primario-tras-el-cancer-colorrectal-de-inicio-temprano-intermedio-y-tardio-un-estudio-retrospectivo-en-un-centro 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2401/risk-factors-cancer-types-and-prognostic-significance-of-second-primary-cancer-after-early-intermediate-and-late-onset-colorectal-cancer-a-retrospective-study-in-a-chinese-high-volume-cancer-center 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2398/evaluacion-de-la-mesotelina-como-un-blanco-inmunoterapeutico-para-las-celulas-t-endogenas 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2398/evaluating-mesothelin-as-an-immunotherapeutic-target-for-endogenous-t-cells 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2397/la-edicion-del-arn-a-nivel-de-celula-unica-identifica-a-adar1-en-las-celulas-t-como-un-regulador-clave-del-agotamiento-inmunitario-y-la-resistencia-anti-pd-1-en-el-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2397/single-cell-rna-editing-identifies-t-cell-adar1-as-a-key-regulator-of-immune-exhaustion-and-anti-pd-1-resistance-in-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2389/inmunoterapia-y-toma-de-decisiones-quirurgicas-en-el-cancer-colorrectal-asociado-al-sindrome-de-lynch-implicaciones-para-el-manejo-personalizado-y-la-revision-de-las-guias-clinicas 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2389/immunotherapy-and-surgical-decision-making-in-lynch-syndrome-associated-colorectal-cancer-implications-for-personalized-management-and-guideline-revision 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2385/la-quimioinmunoterapia-permite-implementar-estrategias-adaptativas-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2385/chemoimmunotherapy-enables-adaptive-strategies-in-locally-advanced-mss-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2384/bloqueo-dual-de-ctla-4-pd-1-frente-a-anti-pd-1-en-cancer-colorrectal-metastasico-msi-h-beneficio-temprano-en-la-supervivencia-y-predictores-clinicos-exploratorios 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2384/dual-ctla-4-pd-1-blockade-versus-anti-pd-1-in-msi-h-metastatic-colorectal-cancer-early-survival-benefit-and-exploratory-clinical-predictors 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2380/terapia-dirigida-a-braf-en-tumores-no-melanoma-con-mutacion-braf-una-revision-sistematica-de-la-eficacia-que-es-amplia-pero-modulada-segun-el-tipo-histologico 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2380/braf-targeted-therapy-in-non-melanomatous-braf-mutant-tumours-a-systematic-review-of-broad-but-histology-modulated-efficacy 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2377/biomarcadores-emergentes-para-la-deteccion-precoz-del-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2377/emerging-biomarkers-for-early-detection-of-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2372/descubrimiento-de-un-nuevo-y-potente-peptido-dirigido-a-kras-g12v-con-actividad-antiproliferativa-contra-celulas-de-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2372/discovery-of-a-novel-and-potent-kras-g12v-targeting-peptide-with-antiproliferative-activity-against-colorectal-cancer-cells 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2371/los-factores-clinicos-estan-mas-fuertemente-asociados-con-el-pronostico-que-las-alteraciones-geneticas-en-el-cancer-colorrectal-de-inicio-temprano-un-estudio-retrospectivo-de-cohortes 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2371/clinical-factors-are-more-strongly-associated-with-prognosis-than-genetic-alterations-in-early-onset-colorectal-cancer-a-retrospective-cohort-study 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2370/un-mecanismo-dual-de-evasion-inmune-moldea-el-panorama-genetico-e-inmunogenico-de-los-tumores-colorrectales-con-deficiencia-en-la-reparacion-de-errores 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2370/dual-mechanism-of-immune-escape-shapes-the-genetic-and-immunogenic-landscape-of-mismatch-repair-deficient-colorectal-tumours 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2365/la-decoccion-sanwu-huangqin-induce-la-ferroptosis-en-las-celulas-de-cancer-colorrectal-al-activar-la-ferritinafagia-mediada-por-ncoa4-fth1 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2365/sanwu-huangqin-decoction-induces-ferroptosis-in-colorectal-cancer-cells-by-triggering-ncoa4-fth1-mediated-ferritinophagy 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2362/los-degradadores-moleculares-que-se-unen-a-hur-suprimen-el-cancer-colorrectal-con-mutacion-en-el-gen-braf 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2362/molecular-glue-degraders-of-hur-suppress-braf-mutant-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2357/sonda-fluorescente-de-infrarrojo-cercano-nir-ii-dirigida-a-vegfr2-para-la-obtencion-de-imagenes-precisas-y-la-guia-quirurgica-del-cancer-de-ovario 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2357/vegfr2-targeted-nir-ii-fluorescent-probe-for-precise-imaging-and-surgical-navigation-of-ovarian-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2351/la-lidocaina-potencia-los-efectos-antitumorales-del-sorafenib-y-el-gw5074-en-celulas-de-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2351/lidocaine-enhances-antitumor-effects-of-sorafenib-and-gw5074-in-colorectal-cancer-cells 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2349/la-combinacion-del-inhibidor-de-kras-g12c-adagrasib-con-inmunoterapia-anti-pd-1-mejora-la-supervivencia-global-y-previene-la-recurrencia-en-modelos-preclinicos-de-metastasis-cerebrales 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2349/combining-the-kras-g12c-inhibitor-adagrasib-with-anti-pd-1-immunotherapy-improves-overall-survival-and-prevents-recurrence-in-preclinical-models-of-brain-metastasis 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2340/hidrogel-anaerobico-inyectable-que-contiene-clostridium-butyricum-para-la-administracion-local-de-hidrogeno-en-el-tratamiento-del-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2340/injectable-anaerobic-hydrogel-loading-clostridium-butyricum-for-local-hydrogen-therapy-against-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2338/ausencia-de-coexistencia-entre-la-amplificacion-de-her2-y-la-inestabilidad-de-microsatelites-deficiencia-de-reparacion-de-errores-dmmr-msi-en-una-amplia-cohorte-multicentrica-de-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2338/absence-of-co-occurrence-between-her2-amplification-and-dmmr-msi-in-a-large-multicentric-colorectal-cancer-cohort 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2337/impacto-de-la-certificacion-del-oncologo-medico-en-los-resultados-de-supervivencia-en-el-cancer-colorrectal-metastasico-evidencia-del-estudio-observacional-scrum-japan-monstar-screen 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2337/impact-of-medical-oncologist-certification-on-survival-outcomes-in-metastatic-colorectal-cancer-evidence-from-the-scrum-japan-monstar-screen-observational-study 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2334/tratamiento-satisfactorio-del-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-y-disfuncion-hepatica-mediante-una-terapia-basada-en-encorafenib 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2334/successful-management-of-braf-v600e-mutated-metastatic-colorectal-cancer-with-liver-dysfunction-using-encorafenib-based-therapy 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2333/farmacoterapia-personalizada-del-cancer-colorrectal 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2333/personalized-pharmacotherapy-of-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2332/desarrollo-y-evaluacion-in-vivo-de-marcadores-de-pet-marcados-con-18-f-que-se-unen-de-forma-covalente-al-kras-g12c-para-el-diagnostico-no-invasivo-del-cancer-y-el-seguimiento-del-tratamiento 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2332/development-and-in-vivo-evaluation-of-18-f-labeled-pet-tracers-covalently-targeting-kras-g12c-for-noninvasive-cancer-diagnosis-and-therapy-monitoring 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2331/de-la-dosis-a-la-exposicion-una-nueva-perspectiva-sobre-los-fluoropirimidinicos-como-posibles-moduladores-de-los-puntos-de-control-inmunitario-en-los-canceres-gastrointestinales 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2331/from-dose-to-exposure-rethinking-fluoropyrimidines-as-immune-checkpoint-partners-in-gastrointestinal-cancers 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2330/terapia-con-celulas-t-modificadas-con-receptores-quimericos-dirigidos-a-la-guanilato-ciclasa-2c-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-07 monthly 0.5 https://crcwarriors.org/articulo/2330/guanylyl-cyclase-2c-targeted-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-metastatic-colorectal-cancer 2026-07-07 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-07-06 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-07-06 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-07-06 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-07-04 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-07-01 monthly 0.4